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Abstract 
Trichosanthin(TCS) is a type I ribosome inactivating protein 
(RIP) extracted from the root tuber of Chinese medicinal plant 
Trichosanthes kirilowii. It possesses broad spectrum of biological and 
pharmacological activities, including abortifacient,anti-HIV and 
antitumour activities. However, it is nephrotoxic and strongly 
immunogenic, and therefore, its immunogenicity and nephrotoxicity 
needs to be reduced to make it a better therapeutic agent. 
ICS is a protein without cysteine residue. By site-directed 
mutagenesis , cysteine residues can be introduced at suspected 
antigenic sites of the protein. Dextran T40 was coupled to the cysteine 
residue by an alkylation method which coupled dextran only to the 
sulphydryl group . As the selected sites are distal from the active site 
cleft , as seen from the 3-dimensional structure of TCS molecule ( 
displayed by the computer software Quanta run on a Silicon Graphic 
Workstation), there was site specific masking at the antigenic epitopes 
but not the active site of TCS. The conjugate possessed the advantage 
of low antigenicity but minimal reduction in its biological activities. 
The increase in molecular mass also lowered its filtration across the 
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glomerular membrane and therefore decreased its nephrotoxicity and 
increased its plasma half-life. 
Using computer program(Sequence Analysis Software 
Package,by Genetic Computer Group) two potential antigenic sites 
were selected. They are Arginine 29 and lysine 173. Site-directed 
mutagenesis using Polymerase Chain Reaction (PCR) technique was 
used to mutate the selected amino acid residues to cysteines and 3 
mutants were produced. They are R29C(Arg29 mutated to cysteine) 
and K173C (lys 173 mutated to cysteine), and double mutant (both lys 
173 and Arg 29 mutated to cysteines). The proteins were successfully 
expressed in Escherichia coli (BL21,DE3, pLysS) and purified with 
CM-sepharose column and FPLC with Mono-S column. The three 
mutated TCS proteins were coupled to dextran T40 successfully by an 
alkylation method via the sulphydryl groups. 
The immunogenicity of both DX-R29C and DX-K173C 
(conjugates of dextran T40 with R29C and K173C respectively) were 
found to be significantly lower than nTCS. However,the DX-
R29CK173C (conjugate of dextran with R29C K173C ) could not get 
a greater reduction in immunogenicity , this may be due to inability of 
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dextran to couple to both sites simultaneously. The biological activities( 
both in vitro and in vivo) of DX-R29C and DX-K173C have been 
tested. The ribosome-inactivating activity , abortifacient activity and the 
anti-tumour activity were all found to be retained. There was only slight 
reduction in the ribosome inactiviting activity and abortifacient activity. 
This was not unexpected as the two selected coupling sites were both 
far away from the active site cleft. 
Acute infusion of TCS causes renal dysfimction . The mechanism 
and the site of damage were uncertain, but seems to be functional 
related to the renal tubules. In the present study, a long term (10 days) 
study was performed to evaluate the effect of single injection of TCS 
on the function and morphology of rat kidney. Results indicated that 
administration of TCS caused a dose dependent decrease in the 
creatinine clearance with mild degree of small molecular weight 
proteinuria. There were subtle structural alteration in the renal tubules 
with major lesion found in the proximal tubule . Scattered tubular cell 
necrosis and increase in the number and size of lysosomes were 
observed. These findings were consistent with drug induced tubular 
toxicity, resulting in reduction of glomerular filtration rate and tubular 
proteinuria. Such toxicity may be mediated through intracelluar events 
iv 
induced by TCS. In conclusion , coupling of dextran T40 to 29th and 
173rd positions was able to reduce the nephrotoxic effect of TCS as 
indicated by the much smaller reduction in the creatinine clearance and 
UNaV. This demonstrates that the nephrotoxic effect of TCS was 
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Naming of TCS mutants and modified TCS proteins 
There were three mutant trichosanthins constructed in this study : 
R29C (mutation of arginine 29 to cysteine), 
K173C (mutation of lysine 173 to cysteine), 
R29C K173C ( double mutation of both arginine 29 and lysine 173 to 
cysteine). 
The mutated TCS genes were named as R29C mutant, K173C mutant 
and R29C K173C double mutant respectively. 
The plasmids housing the mutated TCS genes were pET R29C, pET 
K173C and pET R29C K173C. 
The modified TCS proteins were just named as R29C, K173C and 
R29CK173C. 
The conjugates of the modified TCS proteins with dextran T40 were 
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conjugate 
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IgA immunoglobulin A 
IgE immunoglobulin E 
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mem minimum essential medium 
. mg minigram 
min minute 
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mRNA messenger RNA 
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Chapter 1 Introduction 
Trichosanthin (TCS) is the active ingredient of Chinese medicine 
Tian-hua-fen. It is isolated from the root tuber of Trichosanthes 
kirilowii Maximowicz of the Cucurbitaceae family. The discovery that 
TCS can inhibit the replication of type I human immimo-deficiency 
virus (HIV-1) in vitro (McGrath et al .,1989) has aroused considerable 
research interests. However, anaphylactic responses appeared after 
administration of TCS to HIV-infected patients. As a protein, TCS 
elicits antibody responses such as IgG and IgE production (Ng et 
a/., 1992 ,Xu et al1992), which limits its multiple administration. In 
the past, attempts have been made to reduce its allergenicity by 
coupling it to dextran to mask the antigenic site using dialdehyde 
method. Although the immunogenicity was significantly reduced, the 
biological activity was also diminished significantly(Ko et al ,1992 , Ko 
• et al，1993). One of the possible reasons for the drastic reduction in 
bioactivities was that the coupling was not site specific and the dextran 
might block the active site cleft of TCS. Therefore, it is better to 
couple dextran to TCS in a site specific maimer. The sites selected 
should be potential antigenic sites and also far away from the active site 
cleft. The immunogenicity and biological activities of the conjugate are 
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tested. It was also shown in a previously study that acute infusion of 
TCS results in reduction of glomerular filtration rate and such decrease 
is not observed when TCS is coupled to dextran T40 (Ko et a/.,1994). 
The nephrotoxicity of TCS and the effect of coupling on the 
nephrotoxicity are also studied. 
1.1 Physical and Chemical Properties TCS 
Trichosanthin is a highly basic protein with a pi value of 9.4. 
(Wang et al., 1985). The cDNA of TCS codes for a prepropeptide of 
289 amino acids(Shaw et a/.,1991). The first 23 residues is a 
consensus secretory signal peptide while the last 19 amino acids 
formed a propeptide which is cleaved in post-translational 
processing(Chow et a/.,1990). The mature TCS protein consists of 247 
amino acids and there is no cysteine residue(Chow et a/.,1990 , Shaw 
et a/.,1991). The amino acids and DNA sequence of TCS are shown in 
fig. la. The molecular mass is 27140 dalton as calculated from its 
amino acid composition(Chow et al 1990, Shaw et al .,1991). The 
three dimensional structure of TCS has been resolved to 1.73 and 2.6 A 
respectively by two groups(Gao et a/.,1993，Pan et a/.,1993). The 
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pure crystalline TCS contains no carbohydrate and phosphate moiety 
(Wang etal1985). 
1.2 Biological activities 
1.2.1 Ribosome-inactivating activity 
Ribosome-inactivating proteins (RJPs) is group of proteins that 
are potent inhibitors of eukaryotic proteins synthesis. RIPs can be 
classified into two types. Type I RTPs are single chain, basic proteins 
of molecular weight 26 - 30 kDal. Type II RIPs are proteins consist of 
two different polypeptide chains joined through disulphide linkage. 
The A chain is homologous to type I RIP and is responsible for the 
activity of the molecule. The B chain is a galactose-specific lectin that 
binds to cell surfaces. The lectin domain of type II RIPs facilitates the 
internalization of toxin and hence the cytotoxicity of type II RIPs is 
much higher than type I RJPs (Stirpe et al., 1992, Piatak et al., 1992). 
TCS is a type I RIP. It has potent activity in inhibiting protein 
synthesis in reticulocyte lysate system(Yeung et a/.,1988 ’ Wang et al., 
1987). It is highly homologous to ricin A-chain(Zhang et a/.，1986). 
The similarities in secondary structure of the ricins A chain and TCS 
were further demonstrated by circular dichroism analysis (Kubota et 
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al., 1987). There is also tertiary structural similarity between TCS and 
ricin A chain(Monfort et a/.,1987 , Pan et a/.,1993). 
Like ricin, TCS is able to cleave specifically the N-glycosidic 
bond of adeiiine-4324 of 28s rRNA. It was shown that the removal of 
A-4324 interferes with EF-1 and GTP-dependent ammoacyl-tRNA 
binding to ribosomes as well as EF-2-catalysed GTP hydrolysis and 
translocations(Furutani et a/.,1992). This events lead to rapid arrest of 
protein synthesis. 
The active site of TCS has been elucidated by technique of site-
directed mutagenesis(Wong et a/.,1994). Results indicated that 
glutamate 160 is involved in the catalytic reactions. Kinetic studies 
suggested that the carboxylate group of glutamate 160 serves to 
stabilize the transition-state complex. Glutamate 189 serves as a back 
up of the carboxylate group in case the functional group of glutamate 
160 is lost (Figure lb). 
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1.2.2 Abortifacient Activities 
TCS has been used extensively in China to induce early and mid-
term abortion in human with an over 95% success rate (Jin 1985, Liu 
et a/.,1985 , Liu ^^  a/.,1991). After intra-amniotic adminstration of 
TCS to human during mid-term pregnancy pathological changes first 
appeared in the syncytiotrophoblast in placental villi. TCS damages the 
syncytotrophoblast, releasing clumps of disintegrating cell which 
deposited in the intervillous spaces caused blood clotting and hindered 
blood circulation in the placenta. Local circulation failure accelerated 
the necrosis of the placenta which led to functional impairment of the 
placenta and death of the fetus (Jin .,1985). 
TCS is also able to induce abortion during early pregnancy(Liu 
et a/.,1985). TCS was found to increase incidence of follicular artresi 
and degeneration of ovulated oocytes. It also adversely affects the 
compaction of blastomeres and disrupts the formation of 
blastocysts(Tam et al 1985). Moreover, TCS impaired the in vitro 
and in vivo development of trophoblasts and inner cell mass (Chan et 
a/.,1993). 
Besides its abortifacient action, TCS has been used to cure 
various gestational complications such as the retention of dead fetuses 
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in uterus, missed abortion and ectopic pregnancy(Jin 1985 , Egarter 
etal,\99\). 
1.2.3 Anti-tumour Activities 
TCS has been used clinically for the treatment of various 
abnormal growths of trophoblastic cells such as hydratidiform moles, 
malignant moles and choriocarcinomas(Jm., 1985 , Huang .,1987). TCS 
was found to be more active towards choriocarinomas and melanoma in 
vitro (Tsao et aL, 1986 , Tsao et al., 1990). TCS is able to reduce the 
sizes of sarcomas, reticulosarcomas and melanomas in inice(Leimg et 
al 1986 , Pan et a/., 1985). Moreover, it reduces the size of a 
xenograft of human choriocarinoma in male mice and prolongs their 
mean survival time(Wong et al .,1990). 
In order to increase the specificity and hence the toxicity on a 
hepatoma cell line,Wang et ^/.(Wang et al., 1987, Wang et al 1991) 
conjugated 2-iminothiolane-modified TCS to a monoclonal antibody 
against hepatoma. The cytotoxicity of this immunotoxin to the 
hepatoma was greatly enhanced. 
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1.2.4 Immunological Activities 
Multiple infusion of TCS was limited by the strong 
immimogenicity of TCS which elicit antibody responses such as IgG 
and IgE production(Ng et al 1992 , Xu et al 1992). 
Dexamethasone is sometimes administered with the drug in the 
induction of abortion to prevent anaphylactic shock (Jin .’ 1985, Liu et 
al 1991). Anaphylaxis also occur in the treatment of TCS on HIV 
infected patients. However, probably as a result of the weak immune 
system of the HIV infected patient, less than 10% of them showed a 
positive response in producing anti-TCS antibodies(Byer et al .,1990). 
The anaphylactic reactions may be elicited by the activation of 
complement of TCS via the alternative pathway(Chen et al .,1993). 
Sixteen monoclonal antibodies against TCS was found . These 
includes 5 IgE, 8 IgGl, lIgG3, llgA and 1 IgM. From the results of 
competitive binding assay , the 16 monoclonal antibodies fall into 4 
groups of antigenic determinants/epitopes(Gu et al., 1986). 
TCS is also an immunosuppressive agent. TCS at non-cytotoxic 
concentration selectively inhibits the activation , multiplication and 
differentiation of T and B cells, but not natural killer cells(Leung et 
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a/., 1986). Hence , TCS has a complex interaction with the immune 
system. To elucidate the mechanism and minimize the side effects, 
further investigation must be carried out. 
1.2.5 Anti-fflV activity 
TCS can selectively inhibit replication of HIV in both lymphoid 
and mononuclear phagocyte cell lineages in vitro and 
monocyte/macrophages isolated from individual infected with HIV in 
v/vo. The mechanism of TCS in inhibiting HIV replication is still 
unknown. However, it seems that TCS has a selective effect on viral 
nuclei acid synthesis, processing and/or stability(McGrath et a/.,1989), 
or blocks the binding of viral gpl20 , or affects the CD4 cellular 
receptor fusion process(FeiTari .,et al 1991). 
Phases I and II clinical trials has been conducted to assess the 
effectiveness of TCS on subjects with AIDS and AIDS related 
complications(Byers et a/.,1990, Kahn et a/.,1990 ,Mayer et al., 1992). 
TCS was cleared rapidly from the body, with a plasma half life ranging 
from 2.4 to 4.3 hours over the 8-36 ug dose raiige(Kahn et al .,1990). 
The CD4+ cell number was raised, while the serum p24 antigen level 
8 
was reduced .Patients infected with HIV and failing treatment with 
anti-retroviral agent such as zidovudine, got a gain in CD4+ cell after 
Trichosanthin treatment (Byers et al, 1994). However,adverse 
neurological reactions occurred in some patients and led to coma and 
even death in some cases. 
Although TCS was not directly toxic to human brain cell 
aggregate cultures, treatment of brain cell aggregates with supematants 
of HIV-infected macrophage cultures did result in morphological 
alterations including peripheral rarefaction and cytoplasmic 
vacuolation. Therefore, the anti-viral effect of TCS causing the death 
of HIV-infected cells in brain may be due to the production of toxic 
soluble factor(s)(Pulliam et a/.,1991). This hypothesis requires either 
TCS or cytokines crossed the blood brain barrier. However, to the 
limits of detection, no TCS was found in the cerebrospinal fluid(Kahn 
et al, 1990). Besides, there was no significant increase in the level of 
3-endorphin in the cerebral cortex, cerebellum and brainstem of mice 
treated with TCS, showing that TCS does not adversely affect the 
brain(Ng et al., 1993). The treatment of TCS on HIV-infected patients 
may also be complicated by the differential susceptibility and toxicity 
of various immune cell lines to TCS(FerTari et al 1991). 
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1.2.6 DNase-like activity 
TCS has a weak DNase-like activity(Li et a/., 1991). At 
concentration of TCS higher than 500nM, supercoil DNA is nicked to 
open circular form. However, the role of this DNase-like activity 
remains to be explored. 
1.3 Renal Tubular reabsorption and Nephrotoxicity of TCS 
Pharmacokinetic studies on animal and human indicated that 
TCS has very short plasma half life in the order of minutes to 
hours(Kahn et a/., 1990, Ko et a/.,1991). Accumulation of the drug 
in the kidney suggested that it may be an important organ for TCS 
elimination(Lau et al .,1980 , Ko et a/., 1994). Since TCS is a protein 
with low molecular weight, it is filtered and reabsorbed by the kidney. 
TCS competed with hemoglobin for tubular reabsorption through a 
saturable process. Acute infusion of TCS resulted in reduction of 
glomerular filtration rate(Ko et a/., 1994). Renal dysfunction may be 
caused by the ribosome-inactivating action of TCS on tubular cell upon 
reabsorption of the proteins. When a macromolecule dextran was 
coupled to TCS, there was no reduction in GFR. The dextran-TCS 
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conjugate is a large complex and was therefore excluded from 
glomerular filtration. These studies suggest that TCS is nephrotoxic 
only when it is present in the lumen of the renal tubules(Ko et a/., 1991, 
Ko et ai, 1994). 
The mechanism of TCS toxicity may be the direct effect of its 
protein synthesis inhibitory action, which affect cells with continuous 
or high protein turnover. Another possibility may be the basic nature of 
the TCS makes the protein resistant to lysosomal digestion, and 
therefore leads to tubule cell damage by protein 
overloading(Maack., 1992). One of the objectives of my study is to 
confirm and identify the site of TCS induced nephrotoxicity by 
examining the structural and functional alternations. The effect of 
coupling of dextran to TCS was also studied. 
1.4 Objectives and strategies of study 
Several recent developments on the study of TCS makes the 
present study possible. The cDNA(Shaw et a/.,1991) and genomic 
DNA(Chow et al., 1990) of TCS have been cloned. An efficient 
expression system has been developed for the expression of TCS in 
Escherichia.ColiiThvi et al., 1992). The 3-D structure of TCS has also 
been solved by X-ray crystallography (Gao et ai,1993 , Pan et al., • 
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1993). In the present study, using the technique of site-directed 
mutagenesis on TCS cDNA, mutated TCS is produced.The mutated 
TCS proteins were expressed and purified. Dextran T40 was coupled to 
the mutated TCS in a site-specific way. The selected sites were 
potential antigenic sites but not close to active site cleft. 
1.4.1 Dextran-TCS conjugate 
Dextran is a polymer of D-glucose linked predominantly by a-D 
(1-6) linkages(Aspinall, 1983). Dextran is non-toxic, water soluble and 
available in a wide range of molecular sizes. It can be coupled to 
protein by various chemical methods. 
Coupling to dextran has the advantage of increasing the plasma 
half life but reducing the immunogenicity of a drug(Ko et al, 1991, Ko 
et al, 1992). Thus multiple infusion and hypersensitivity reaction can be 
avoided. The increase in molecular mass prevents the drug from loss by 
glomerulus filtration. The reduction in immunogenicity may be the 
result of the masking of antigenic epitopes of the molecule(Broome 
.,1965 , S e p p a l a a / , 1989). 
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There are numerous methods of activating dextran for coupling 
to protein molecules. Two of the common methods are the dialdehyde 
method and the alkylation method(Tam et a/., 1976). In the dialdehyde 
method , dextran is oxidized by periodate to form polyaldehyde 
dextran which can be linked to the amino groups of protein molecule. 
This method has been used to couple dextran T40 to TCS 
siiccessflilly(Ko et a/., 1991).This method has the advantage of being 
applicable to almost all proteins which possess amino groups on its 
surface. As more than one amino group are usually present on protein 
surface, this method suffers from the disadvantage that the coupling is 
not site specific and more than one dextran may be linked to the same 
protein molecule. 
The alkylation method involves the use of CNBr as the activating 
agent(Tam et a/., 1976).The activated dextran can than be anchored 
onto the sulphydryl group of a protein through a carbon bridge. The 
method will be site specific for proteins with only a few surface 
sulphydryl groups. 
In the present study, the alkylation method of coupling was 
employed. TCS is a protein without cysteine residue, the creation of 
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cysteine residue at specific site of the protein will make the coupling by 
this method site-specific. 
1.4.2 Selection of Potential Antigenic Eptitopes and Mutation Sites 
In order to decrease the immunogenicity with minimal loss in 
bioactivities, potential antigenic sites which are far away from the 
active site cleft should be selected as the mutation and coupling sites. 
A computer program and the 3-D structure of TCS were used to 
calculate the degree of immunogenicity of each amino acid of TCS 
molecule. The program used was Sequence Analysis Software 
Package. The program calculates the antigenic index by summing up 
several weighted measures of secondary structure(Manual of Sequence 
Analysis Software Package, Genetic Computer Group, Section 10-35 
to 10-38) . Five criteria were considered in this method. Firstly, the 
probability of the amino acid being on the surface of the protein 
molecule. Secondly, the hydrophilicity of the amino acid. Thirdly, the 
chain flexibility and fourth criteria is the probability of forming loops 
or turns. Lastly, the amino acid residue should have its side chain 
points outward of TCS and not interacting with adjacent residues. Two 
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sites with the highest antigenic index were selected. They were the 
29th amino acid (an arginine residue) and 173rd amino acid (a lysine 
residue). 
From the 3D structure of TCS as determined by X-Ray 
crystallography at resolution of 2.6 A , the 2 sites are far away from the 
active site cleft of TCS(fig. Ic , Id , 1 e). Therefore, dextran molecule 
coupled to any of the 2 sites should not sterically hinder the binding of 
substrate to the active site glutamate 160. 
15 
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97 G A T A T C CCT C T G T T A CGT TCC T C T C T T C C A G G T T C T C A A C G C T A C G C A 144 
49 L e u lie H i s L e u T h r A s n Tyr A l a A s p G l u T h r l i e S e r V a l A l a lie 64 
145 T T G A T C CAT C T C A C A A A T TAC G C C G A T G A A A C C A T T T C A G T G G C C A T A 192 
65 A s p V a l T h r A s n V a l T y r lie M e t G l y T y r A r g A l a G l y A s p T h r S e r 80 
193 G A C G T A A C G A A C G T C TAT ATT A T G G G A T A T C G C G C T G G C G A T A C A T C C 240 
^81 T y r P h e P h e A s n G l u A l a Ser A l a T h r G l u A l a Ala' Lys T y r V a l P h e 96 
2 4 1 T A T T T T T T C A A C G A G GCT TCT G C A A C A G A A G C T G C A A A A T A T G T A T T C 288 
L y s A s p A l a M e t A r g Lys V a l T h r L e u Pro T y r S e r G l y A s n T y r G l u 112 
289 A A A G A C G C T A T G C G A A A A GTT A C G CTT C C A T A T T C T G ^ A A T T A C G A A 336 
113 A r g L e u G i n T h r A l a A l a G l y L y s lie A r g G l u A s n lie Pro L e u G l y 128 
337 A G G C T T C A A A C T GCT G C A GGC A A A A T A A G G G A A A A T A T T C C G CTT G G A 384 
III L e u Pro A l a Leu A s p S e r Ala lie T h r T h r L e u P h e T y r T y r A s n A l a 144 
385 C T C C C T G C T T T G GAC A G T GCC A T T A C C A C T T T G T T T T A C T A C A A C G C C 432 
145 A s n S e r A l a A l a S e r A l a Leu M e t V a l L e u l i e G i n S e r T h r S e r G l u 160 
433 A A T T C T G C T G C G T C G G C A CTT A T G G T A C T C A T T C A G T C G A C G T C T G A G 480 
Ala Ala Arg Tyr Lys Phe He Glu Gin Gin lie Gly Lys Arg Val Astj 176 
4 8 1 G C T G C G A G G T A T A A A TTT ATT G A G C A A C A A A T T G G G A A G C G T GTT G A C 528 
177 L y s T h r Phe L e u Pro S e r Leu A l a lie lie S e r L e u G l u A s n S e r T r p 192 
529 A A A A C C T T C C T A C C A A G T T T A G C A A T T A T A A G T T T G G A A A A T A G T T G G 576 
S e r A l a Leu S e r Lys G i n H e G i n lie A l a S e r T h r A s n A s n G l y G i n 208 
5 7 7 T C T G C T C T C T C C A A G C A A ATT C A G A T A G C G A G T A C T A A T A A T G G A C A G 624 
209 G l u S e r Pro V a l V a l Leu lie A s n A l a G i n A s n G i n A r g V a l T h r 224 
625 T T T G A A A G T C C T G T T G T G CTT A T A A A T G C T C A A A A C C A A C G A G T C A C G 672 
225 l i e T h r A s n V a l A s p A l a G l y V a l V a l T h r S e r A s n lie A l a L e u L e u 240 
673 A T A A C C A A T G T T G A T G C T G G A G T T G T A A C C T C C A A C A T C G C G T T G C T G 720 
2 4 1 L e u A s n -Arg A s n A s n M e t A l a '247 
7 2 1 C T G A A T A G A A A C A A T A T G G C A 7 4 1 
Figure la : The DNA and deduced amino acid sequence of mature TCS 
(Shaw et al., 1991). 
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Glu 160 a U S a m r^--N~terminal 
丨—赞 
Figure lb : The active site (El60) and active site cleft of 
Trichosanthin. 
Glu 160 I 
(active site) g p Vv 
Figure Ic : Previous diagram in different orientation showing 
29th position more clearly. 
^ ^ 17 
Lys 173 ^ ^ ^ 
Figure Id : Previous diagram in differrent oritentation 
showing 173 rd position more clearly. 
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Chapter 2 Materials and Methods 
2.1 General Techniques 
2.1.1 SDS-polyacrylamide gel electrophoresis(SDS-PAGE) 
All SDS-Polyacrylamide gels were run with the Mini-PROTEAN II 
electrophoresis cell (BioRad Laboratories, Inc.) The cell was assembled 
according to the manufacturer's instructions. 
‘Running gel (12%) was prepared as follows: 
H2O 1.6 ml 
1.5M Tris-Cl (pH8.8) 1.3 ml 
30% Acrylamide 2.0 ml 
10% (w/v) SDS 50 ul 
10% (w/v) ammonium persulphate 50 ul 
TEMED 2 ul 
3.5 ml of the running gel solution was poured into the gap between the 
glass plates. 1 ml isopropanol was added to keep the solution out of 
atmospheric oxygen and to remove air bubbles on solution surface. The 
polymerization should be completed in 15 minutes. 
Stacking gel (3%) was prepared as follows: 
H2O 1.4 ml 
30% Acrylamide 0.33 ml 
1.0 M Tris-Cl (pH 6.8) 0.25 ml 
10% (w/v) SDS 20 ul 
10% (w/v) ammonium persulfate 20 ul 
TEMED 2 ul 
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After the running gel was set, the isopropanol layer was removed. 2 ml of 
stacking gel solution was poured and the comb was inserted to the gap 
between the glass plates 
The volumes of protein samples were adjusted to 15 ul with water and 15 
ul of 2x SDS gel loading buffer was added, the samples were boiled for 5 
minutes and then applied to the wells. The gel was run at 30 mA until the 
bromophenol blue reached the bottom of the running gel (about 45 
minutes). The gel was removed from the electrophoresis cell and then can 
be stained with Coommassie Brilliant Blue . 
After electrophoresis, the gel was immersed in 100 ml staining solution 
(0.15% (w/v) Coommassie Brilliant Blue R-250, 31.25% (v/v) ethanol, 
10% (v/v) acetic acid) for 30 minutes at 70�C . The gel was then destained 
by soaking it in destaining solution (25 % (v/v) ethanol ’ 8 % (v/v) acetic 
acid) at 70°C for 4-8 hours. The destaining solution was changed several 
times until the destaining was completed. 
2.1.2 Lowry Protein Determination 
The assay was according to the method of Lowry (1952). For assay of 
protein concentrations, 0.2 ml aliquots of protein samples were mixed with 
2 ml of Reagent A (2 ml of 2% C11SO4.5H2O，2 ml of 4% KNa-tartrate, 96 
ml of 3% NaiCOs in 0.1 M NaOH). The mixture was incubated at room 
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temperature for 10 minutes. Then 0.2 ml of Reagent B (1:1 dilution of 
Phenol-ciocalteau Reagent in water) was added and incubated for 40 
minutes at room temperature. Protein concentrations were read at OD 
750mn against a standard curve with serial dilutions of BSA of Img/ml 
following the same procedure. 
2.1.3. Liquid Scintillation Counting 
A Beckman LS 1801 liquid scintillation counter was used for ^H and ^^ S 
countings. The scintillation fluid used was prepared by mixing 1 litre of 
toluene, 6 g ofPPO and 0.05 g of POPOP. Filters were placed in plastic 
scintillation vials containing 4 ml of scintillation fluid. 
2.2 Site-directed mutagenesis of Trichosanthin 
2.2.1 Ethanol precipitation of DNA 
0.1 volume of 3.0 M sodium acetate (pH 5.2 ) and 2 volume of cold 100% 
ethanol were added to a DNA solution. The DNA was precipitated at -
70�C for 30 minutes. The precipitate was pelleted at 12000 g for 20 
minutes at 4°C in a microfiige. The pellet was washed with 70 % ethanol 
.After centrifiigation at 12000 g for 10 minutes at 4°C，the pellet was dried 
in SpeedVac (Savant Instruments Inc.) and dissolved in H2O , TE (pH 
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8.0)(10 mM Tris-Cl, ImM EDTA, pH 8.0) or a suitable buffer at desired 
concentration , 
2.2.2. Spectrophotometric quantification of DNA 
Spectrophotometer (Hitachi 100-10 UV-VIS) was used routinely for 
quantification of nucleic acid. An OD280 of 1 corresponds to 50 ug/ml for 
double-stranded DNA, 40 ug/ml for single-stranded DNA and 20 ug/ml for 
single-stranded oligonucleotides. 
2.2.3. Minipreparation of Plasmid DNA 
The method was adopted from Maniatis et al. (1989) with minor 
modifications. A single bacterial colony was inoculated into 2 ml of LB 
medium containing the appropriate antibiotic in a capped test-tube. The 
culture was incubated overnight at 37°C with vigorous shaking. Bacterial 
pellet of 1.5 ml culture was collected by centrifugation at 12,000 g for 5 
minutes in a microfuge. The pellet was resuspended in 100 ul PI (50 mM 
Tris-Cl pH7.5 , lOmM EDTA and lOOug/ml RNase) containing 100 ug/ml 
RNase. After 100 ul P2 (0.2 M NaOH and 1 % SDS) was added, the 
mixture was allowed to stand on ice for 5 minutes. Then 100 ul P3 (2.55 
M potassium acetate pH 4.8) was added followed by standing on ice for 
15 - 30 minutes. Cell debris and chromosomal DNA were removed by 
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centrifugation at 12,000 g for 15 minutes in a microfiige. The supernatant 
was transferred to a fresh microfiige tube and was re-centrifuged if white 
precipitate was present. The plasmid DNA was recovered by ethanol 
precipitation and dissolved in 15 ul H2O. 
2.2.4. Preparation of plasmid DNA using Qiagen-pack 100 
Cartridge 
This method was modified from the 3rd Edition of the Qiagen Application -
Protocol A single bacterial colony was inoculated into 400 ml of LB 
medium containing the appropriate antibiotic. The culture was incubated 
overnight at 37°C with vigorous shaking. Bacterial pellet of the culture 
was collected by centrifugation at 5,000 rpm for 5 minutes at 4°C (Hitachi 
high Speed Centrifuge SCR20B with RPR 12-2 rotor). The pellet was 
resuspended in 10 ml PI containing 100 ug/ml RNase. After 10 ml P2 was 
added, the mixture was allowed to stand on ice for 5 minutes. Then 10 ml 
P3 was added followed by standing on ice for 15 - 30 minutes. Cell debris 
and chromosomal DNA were removed by centrifugation at 13,000 rpm for 
15 minutes at 4°C (RPR 20-2 rotor). The supernatant was transferred to a 
fresh tube and was re-centrifuged for 30 minutes at 4°C to obtain a 
supernatant of about 30 ml. 
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A QIAGEN-pack 100 column (QIAGEN Inc.) was equilibrated with 3 ml 
of QBT (750 mM NaCl, 50 mM MOPS, 15% ethanol, pH 7.0, 0.15% 
Triton X-100). The flow was maintained by gravity. 1/3 volume (about 
10 ml) of the supernatant from the previous steps was applied to the 
column. The column was then washed with 10 ml QC (1.0 M NaCl, 50 
mM MOPS, 15% ethanol, pH 8.2). The above procedure was repeated 
two more times to purify the plasmid DNA in the remaining supernatant. 
The plasmid DNA was pooled together and was recovered by isopropanol 
precipitation. 0.7 volume of isopropanol was added to the eluted DNA. 
After incubated on ice for 15 minutes, the DNA was recovered by 
centrifligation at 13,000 rpm (RPR 18-3 rotor) for 20 minutes at 4�C. The 
pellet was washed with 70% ethanol and lyophilized . The DNA was 
dissolved in 200 ul of water or TE (pH 8.0) (lOmM Tris-Cl, ImM EDTA, 
pH 8.0) and stored at -20°C. 
2.2.5. Preparation of Plasmid DNA using Magic™ Minipreps 
DNA Purification kit from Promega 
The following procedure is based on the method recommended by the 
supplier. A single bacterial colony was inoculated into 5 ml of LB medium 
containing the appropriate antibiotic in a capped test-tube. The culture 
was incubated overnight at 37°C with vigorous shaking. Bacterial pellet 
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was collected by centrifugation at 12,000g for 5 minutes in a microfiige. 
The pellet was resuspended in 200 ul PI (50mM glucose, 25 mM Tris.CI 
pH 8.0, 10 mM EDTA) containing 100 ug/ml RNase. After 200 ul P2 (0.2 
N NaOH, 1% SDS) was added, the mixture was allowed to stand on ice 
for 5 minutes. Then 200 ul P3 (prepared by mixing 60ml of 5M 
potassium acetate, 11.5ml glacial acetic acid and 28.5 ml distilled water), 
was added followed by standing on ice for 15 - 30 minutes. Cell debris 
and chromosomal DNA were removed by centrifugation at 12,000g for 15 
minutes in a microfuge. The supernatant was transferred to fresh 
microfuge tube and was re-centrifuged if white precipitate was present. 1 
ml Magic™ Minipreps DNA Purification Resin was added to the 
supernatant. A Magic™ Minipreps Column was attached to a 3 ml syringe 
barrel. The slurry was then pushed gently into the column. The column 
was washed with 2 ml Column Wash Solution. The column was 
centrifuged for 30 seconds in a microfuge to remove the last traces of 
solution. 50 ul of water preheated to 65 - 70°C was applied to the column. 
A new microfuge tube was attached to the outlet of the column. Solution 
containing the plasmid DNA was recovered by centrifiigation at 12,000g 
for 30 seconds in a microfuge. 
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2.2.6. Preparation and Transformation of Escherichia coli 
competent cell 
The following method was adopted from Maniatis et al. (1989) with minor 
modification. Escherichia coli strain DH5a was streaked directly from a 
frozen stock onto the surface of an LB agar plate. The plate was incubated 
overnight at 37°C. Single colony from the plate was transferred to 5 ml 
SOB. The culture was incubated overnight at 37°C. The 5 ml culture was 
inoculated into 50 ml SOB. The cells were grown at 37°C until OD^ 
reached 0.8. The cells were harvested by centrifugation at 5,000 rpm for 
10 minutes at 4�C (Hitachi High Speed Centrifuge SCR20B with RPR 20-
2 rotor). After standing the tubes in an inverted position for 1 minute to 
remove the last traces of medium, the pellet was resuspended in 20 ml of 
ice-cold FSB (10 mM Potassium acetate (pH 7.5), 45 mM MnC12, 10 mM 
CaCl2, 100 mM KCl, 3 mM hexaimninecobalt chloride, 10% (v/v) 
glycerol, pH 6.4). The suspension was kept on ice for 10 minutes. The 
cells were recovered by centrifugation at 5,000 rpm for 10 minutes at 4�C 
(Hitachi High Speed Centrifuge SCR20B with RPR 20-2 rotor). After 
standing the tubes in an inverted position for 1 minute to remove the last 
traces of medium, the pellet was resuspended in 4 ml of ice-cold FSB. 140 
ul of DMSO was added and the suspension was kept on ice for 15 
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minutes. Then an additional 140 ul of DMSO was added. The competent-
cell suspension was dispensed into aliquots of 200 ul each. The aliquots 
was snap-freezed in liquid nitrogen and stored at -70°C until needed. 
Just before use, the competent cells were thaw in ice. Transforming DNA 
(less than 10 ul) was added to competent cells and mixed well. The tubes 
were stored on ice for 30 minutes and then heat-shocked at 42°C for 
exactly 90 seconds. The tubes were rapidly transferred to an ice bath to 
chill the cells for 2 minutes. Then 800 ul of SOC or LB medium was 
added. The cultures were incubated at 37°C for 45 minutes to allow the 
bacteria to recover and to express antibiotic resistance marker encoded by 
the plasmid, 100 to 200 ul of the transformed culture was spreaded onto a 
LB agar plate containing an appropriate antibiotic. After the liquid had 
been absorbed, the plates were incubated at 37�C overnight. 
2.2.7. Agarose Gel Electrophoresis of DNA 
The agarose gels were prepared with 0.5 - 2.0 % (w/v) agarose (Sigma A-
9539) dissolved in Ix TAE (40 mM Tris-acetate and 1 mM EDTA) or Ix 
TBE (90 mM Tris-borate and 2mM EDTA) buffer containing 0.5 ug/ml of 
ethidium bromide. The volume of DNA samples were adjusted to 5 - 60 ul 
with water. 6x gel-loading buffer (0.25 % bromophenol blue and 40 % 
(w/v) sucrose in water) was added to the DNA sample to a final 
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concentration of Ix. After loading the samples into the wells, 
electrophoresis was performed at constant voltage of 50 - 100 V in a gel 
tank containing Ix TAE or Ix TBE. When electrophoresis was finished, 
DNA was visualized on a Spectroline Model TC-302 UV transilluminator 
(302nm) and, if necessary, photographed with a Polaroid MP-4 instant 
camera and Polaroid 667 instant film through a HOYA R (25A) red filter. 
2.2.8. Purification of DNA from Agarose Gel using 
GeneCleanll® (BIOlOl Inc.) kit 
The following procedure worked best with TAE gel. The agarose gel , 
stained with ethidium bromide was observed under ultra-violet 
illumination. The band containing the desired DNA was cut out from the 
« 
gel using a razar blade. The weight of the gel slice was determined and 3 
volumes of 6M Nal solution was added. After melting the gel at 55°C for 
5 minutes, 5 -15 ul Glassmilk® silica matrix was added. The mixture was 
kept on ice for 15 minutes with occasional shaking. The suspension was 
centrifiiged in a microfiige at 13,000 rpm for 1 minute. The pellet was 
washed with 0.7 ml NEW WASH solution. The suspension was then 
centrifuged in a microfiige at 13,000 rpm for 1 minute. The washing 
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procedure was repeated for two more times. The washed pellet was 
resuspended with 10 - 20 ul of water or TE (pH 8.0) (10 mM Tris-Cl, 1 
mM EDTA, pH 8.0) buffer. After incubation at 55�C for 5 minutes, 
supernatant containing the DNA was recovered by centrifugation in a 
microfuge at 13,000 rpm for 1 minute. 
2.2.9. Polymerase Chain Reaction (PCR) 
Site-directed mutagenesis was carried out by PCR using mutagenic primer. 
Oligonucleotide primers were designed in such a way that the mismatches 
were located at the center of the primer with not less than 8 matches on 
both sides. Primers used in the present study are list in Fig.2a 
The following method was based on Maniatis et al. (1989) with 
modification. Plasmids harboring the TCS gene, pET 58210 or 
pTrc58210, were used as templates for the polymerization. Vent™ DNA 
polymerase and lOx amplification buffer were supplied by the New 
England Biolabs. 
5 ul of lOx amplification buffer, 8 ul of dNTP mix (1.25 mM of dATP, 
dCTP, dGTP, dTTP), 5 ul of forward primer (20 uM) and 5 ul of reverse 
primer (20 uM) were mixed together in a 500 ul microfiige tube. Template 
(up to 2 ug) was added to the reaction mixture. Water was added so that 
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final volume of the mixture was 50 ul. The mixture was incubated at 94�C 
for 5 minutes to denature the template DNA. While the tube was still at 
94°C, 2 units of Vent™ DNA polymerase was added. The tube was 
vortexed briefly and was centrifuged to spin down liquid that may attach 
on the surface of the tube. 50 ul of light mineral oil (Sigma M5904, 
Molecular Biology Grade) was overlaid onto the reaction mixture to 
prevent evaporation of the solution during incubation. 
The amplification was carried out under the following cycles: 
Cycle Denaturation annealing Polymerization 
1st 5 mm. at 94°C 2 min. at 50°C 3 min. at iTC 
2nd to 34th 1 min. at 94°C 2 min. at 50°C 3 min. at 72°C 
35th 1 min. at 94°C 2 min. at 5(TC 10 min. at 72°C 
After amplification，the mineral oil was removed. 10 ul of 6 x agarose gel 
loading buffer was added and the sample was loaded to an agarose gel. 
After electrophoresis , the PGR product was recovered by 
GeneCleanII®kit(section 2.2.8) 
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2.2.10 Restriction digestion of DNA 
Restriction digestion of DNA was carried out in a volume of 10 to 80 ul in 
the appropriate buffers(NEBl-4) as suggested by the suppliers. The 
reaction mixture was incubated at 37°C for 3 hours or overnight. After 
digestion, the reaction mixture was analyzed by agarose gel 
electrophoresis. 
2.2.11 Ligation of DNA fragments 
The following procedure described the general conditions for ligation of 
DNA. DNA fragments to be ligated were mixed together. The mixture 
was incubated at 45°C for 5 minutes. Then lOx ligation buffer, provided by 
the supplier, was added to the reaction mixture to a final concentration of 
Ix. 3 to 6 units of T4 DNA ligase (New England Biolabs.) was added and 
the reaction mixture was incubated overnight at 16°C (for sticky end 
ligation). 
2.2.12 Construction of R29C mutant 
PCR mutagenesis and subcloning (fig. 2b) 
Mutagenesis by overlapping primers method was used. The method was 
based on Ho et al., 1989 with modification. Two PCRs were required and 
were performed as described in section 2.2.9. The primers used for the 
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PCR are shown in fig.2a. In the first PGR, using 1 ug pET 58210 as 
template, the primer pET fwd and PR29C rev generated a 0.12kb fragment, 
while Primer C and PR29C gave a 0.45 kb fragment. 
The 0.12 and 0.45 kb PCR fragments were separated from primers and 
template by agarose gel electrophoresis (Section 2.2.7) and was purified 
from the gel using GeneClean II® kit (Section 2.2.8). The recovered DNA 
was dissolved in 15 ul H20. 
Before the second PCR, 0.12 and 0.45 kb PCR fragment was fused by 
denaturing and annealing them in primer extension reaction using 5 ul of 
each the 2 fragments. Then the second PCR was performed with pET 
forward and Primer C as the Primers. The 0.57 kb PCR fragment was 
purified. Finally, the recovered DNA was dissolved in 15 ul H2O. All the 
DNA was digested with restriction enzyme Nco I and Pst I. After agarose 
gel electrophoresis, the cut fragments (0.4 kb) were purified using 
GeneCleanll® kit. The DNA was dissolved in 15 ul H2O. 
5 ug of pET58210 was digested with restriction enzymes BamH I and Pst 
I. After agarose gel electrophoresis, 0.35kb fragment was purified using 
GeneClean® kit and was finally dissolved in 15 ul H2O. 
5 ug of pET 8c was digested with restriction enzymes Nco I and BamH I. 
After agarose gel electrophoresis, the 4.6 kb fragment was purified using 
GeneClean II® kit and was finally dissolved in 15 ul H2O. 
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1 ul of 4.6 kb fragment ofpET 8c, 1 ul of 0.35 kb fragment ofpET58210, 
2 ul of water were mixed together. The mixture was incubated at 45°C for 
3 minutes. 0.5 ul of lOx T4 DNA ligase buffer and 0.5 ul of T4 DNA 
ligase (New England Biolabs, 400 New England Biolabs units per ul) was 
added and the mixture was incubated at 16°C for 4 hours. Then 4 ul of 0.4 
kb PGR fragment was added to the reaction mixture. An additional 0.5 ul 
of lOx DNA ligase buffer and 0.5 ul of T4 DNA ligase were added and the 
mixture was incubated at 16°C overnight. 
The ligation mixture was added to 200 ul of DH5a competent cells. 
Transformation was performed as described in Section 2.2.6. 
Screening of Transformed Colonies 
Plasmid was isolated from transformed colonies by mini-preparation 
(Section 2.2.3). The size of the plasmid was analyzed by agarose gel 
electrophoresis with the pET 58210 as marker. The plasmid was also 
analyzed by restriction digestion with Nco I and BamH I. The mutation 
was finally confirmed by DNA sequencing (Section 2.3). The whole PGR 
generated fragment was sequenced to avoid secondary mutation. 
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2.2.13. Construction of K173C mutant 
PCR mutagenesis and subcloning (fig. 2c) 
Overlapping PCR method was used again. The procedure was similar to 
that for R29C mutant. In the first PCR, two sets of primers. Primer E and 
PK173C rev, pTrc rev and PKi73Cfwd gave 0.15 kb and 0.23 kb fragments 
respectively with pTrc 58210 as the template. The two fragments were 
purified and was fosed by denaturing and annealing them in primer 
extension reaction. The second PCR was done with Primer E and pTrc 
rev as the primers to give a 0.4 kb fragment. The 0.4 kb fragment was 
purified and was dissolved in 15 ul H2O. All the DNA was digested with 
restriction enzyme Pst I and Bam HI to give 0.35 kb fragment . After 
agarose gel electrophoresis, the cut fragments were purified using 
GeneCleanll® kit. The DNA was dissolved in 15 ul H2O. 
5 ug ofpET58210 was digested with restriction enzymes Nco I and Pst 1. 
After agarose gel electrophoresis, 0.4kb fragment was purified using 
GeneClean® kit and was finally dissolved in 15 ul H2O. 
5 ug ofpET 8c was digested with restriction enzymes Nco I and BamH 1. 
After agarose gel electrophoresis, the 4.6 kb fragment was purified using 
GeneClean II® kit and was finally dissolved in 15 ul H2O. 
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1 ul of 4.6 kb fragment ofpET 8c, 1 ul of 0.35 kb fragment of pET58210, 
2 ul of water were mixed together. The mixture was incubated at 45°C for 
3 minutes. 0.5 ul of lOx T4 DNA ligase buffer and 0.5 ul of T4 DNA 
ligase (New England Biolabs, 400 New England Biolabs units per ul) was 
added and the mixture was incubated at 16°C for 4 hours. Then 4 ul of 
0.35 kb PGR fragment was added to the reaction mixture. An additional 
0.5 ul of lOx DNA ligase buffer and 0.5 ul of T4 DNA ligase were added 
and the mixture was incubated at 16°C overnight. 
The ligation mixture was added to 200 ul of DH5a competent cells. 
Transformation was performed as described in Section 2.2.6. 
Screening of Transformed Colonies 
Plasmid was isolated from transformed colonies by mini-preparation 
(Section 2.2.3). The size of the plasmid was analyzed by agarose gel 
electrophoresis with the pET 58210 as marker. The plasmid was also 
analyzed by restriction digestion . The mutation was finally confirmed by 
DNA sequencing (Section 2.3). The whole PGR generated fragment was 
sequenced to avoid secondary mutation. 
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2.2.14 Construction of K173C R29C double mutant 
Subcloning (fig. 2d) 
The R29C K173C double mutant was constructed by subcloning of pET 
R29C and pETK173C. 
5 ug of pETR29C was digested with restriction enzymes Ncol and PstI . 
After agarose gel electrophoresis，the 0.4 kb fragment was purified by 
Geneclean II kit and was finally dissolved in 15 ul H2O. 
5ug of pET K173C was digested with restriction enzymes Bam HI and Pst 
I. After agarose gel electrophoresis the 0.35 kb fragment was purified by 
Geneclean II kit and was finally dissolved in 15 ul H2O. 
5 ug of pET 8C was digested with restriction enzymes Ncol and BamHI, 
After agarose gel electrophoresis , the 4.6 kb fragment was purified by 
Geneclean kit and was finally dissolved in 15 ul H20. 
1 ul of 4.6 kb fragment of pET 8c，1 ul of 0.35 kb fragment of pET 
K173C, 2 ul of water were mixed together. The mixture was incubated at 
45°C for 3 minutes. 0.5 ul of lOx T4 DNA ligase buffer and 0.5 ul of T4 
DNA ligase (New England Biolabs, 400 New England Biolabs units per 
ul) was added and the mixture was incubated at 16°C for 4 hours. Then 4 
ul of 0.4 kb fragment of pET R29C was added to the reaction mixture. An 
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additional 0.5 ul of lOx DNA ligase buffer and 0.5 ul of T4 DNA ligase 
were added and the mixture was incubated at 16°C overnight. 
The ligation mixture was added to 200 ul of DH5a competent cell. 
Transformation was performed as described in Section 2.2.6. 
Screening of Transformed Colonies 
Plasmid was isolated from transformed colonies by mini-preparation 
(Section 2.2.3). The size of the plasmid was analyzed by agarose gel 
electrophoresis with the pET 58210 as a marker. The mutation was finally 
confirmed by DNA sequencing (Section 2.3). 
2.3 DNA sequencing 
The subcloned mutated TCS genes were verified by DNA sequencing. 
Sanger's method of DNA sequencing was employed in this purpose. 
Double stranded plasmids were used as template. 
2.3.1 DNA Sequencing Reaction 
T7 Sequencing kit (Pharmacia) was used to carry out the reaction. The 
following method was based on the manual provide by the supplier. 
8 ul of water containing 1 - 2 ug of plasmid DNA was added to 2 ul of 2 
M NaOH. The mixture was kept at room temperature for 10 minutes to 
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allow denaturation of the template. Then 3 ul of 3 M sodium acetate (pH 
4.5), 7 ul of water was added to neutralize the solution. The DNA was 
precipitated by adding 60 ul of chilled absolute ethanol. The solution was 
placed at 
-70° C for 30 minutes. The DNA was recovered by centrifugation at 
13,000 rpm for 20 minutes at 4�C in a microfuge. The pellet was washed 
with 70% ethanol and lyophilized. The dried pellet was then dissolved in 
10 ul of water, 2 ul each of annealing buffer and 5 ng/ ml primer solution 
was added to the template solution. The mixture was incubated at 37°C 
for 20 minutes and then at room temperature for 10 minutes. 3 ul of 
labeling mix, 1 ul of [a-35S]dATP or [a-35S]dCTP (10 mCi/ ml, > 1000 
Ci/ mmol, Amersham SJ304) and 2 ul of diluted T7 DNA polymerase (1.5 
units/ ul, diluted with enzyme diluting buffer) were added to the reaction 
niixture. The mixture was incubated at room temperature for 5 minutes. 
During incubation, 2.5 ul of A-, G-, C-, and T-Mix Short was added to 
four labeled fresh microfuge tubes and were prewarmed at 37°C. After 
incubation, 4.5 ul of the reaction mixture was added to each of the four 
prewarmed sequencing mixes. The four tubes were incubated at 37 C for 
5 minutes. Then 5 ul of Stop solution was added to each tube. The 
sample was then kept at -20°C until use. 
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2.3.2 DNA Sequencing electrophoresis 
Preparation of 6% polyacrylamide gel 
42 g of urea (Molecular Biology Reagent, Sigma), 14.5 ml of 40% 
acrylamide stock solution (38% (w/v) acrylamide, 2% (w/v) N,N’-
methylene-bisacrylamide) and 10 ml of 1 Ox TBE buffer were added to 30 
ml of water. Urea was dissolved by warming gently on a hot plate. After 
all the urea had been dissolved, water was added to make up the final 
volume to 100 ml. The acrylamide solution was then filtered through a 
Millipore 0.22 jum filter. The solution was degassed using vacuum pump. 
Just before pouring the gel, 0.8 ml of 10% of freshly prepared ammonium 
persulfate and 80 ul of TEMED (BioRad Laboratories) were added to the 
monomer solution. 
Treatment of the glass plate surface for gel casting 
The surface of a pair of glass plates (20 x 40 cm) were cleaned with 
distilled water and ethanol thoroughly. The entire surfaces of the plates 
which contact the gel were wiped with repel-silane (dimethyldichlorosilane 
solution 2% (w/v) in 1,1,1 ,-trichloroethane) using lint-free tissue paper. 
Finally, the surfaces were wiped with ethanol again. 
Gel casting 
39 
A pair of 0.4 mm thick spacers was placed between the treated glass 
plates. The margins and the bottom of the plate sandwich were sealed 
with tape. Then it was laid in a tray so that the plates inclined at an angle 
of about 20°. Immediate after adding the catalysts, the gel was poured into 
the gap between the plates. Great care was taken to avoid trapping of air 
bubbles inside the gel. The plate sandwich was placed horizontally and a 
sample comb was inserted into the gap between the plates. The gel was 
allowed to set for 30 minutes. 
Electrophoresis 
When the polymerization was complete, the comb was removed and the 
wells were washed thoroughly with water to remove any trace of 
unpolymerized monomer. The gel plate sandwich was then assembled 
onto the gel tank. The upper and the lower buffer reservoirs were filled 
with Ix TBE buffer. The gel was pre-run at 1500 V for 30 minutes. 
Before loading, the sample was heated at 80°C for 2 minutes. 3 ul of 
sample was loaded into the well using a sequencing pipette (Drummond). 
The gel was then run at constant voltage of 1500 V. Cooling and even 
heating was facilitated by placing a metal plate onto the sandwich. 
Running time was dependent on the distance between the sequence of 
40 
interest and the primer annealing site. Usually, electrophoresis last for two 
to six hours. After the electrophoresis was complete, the glass plates were 
dissembled under the fixing solution (10% (v/v) acetic acid). The gel was 
fixed for 10 minutes. Then the gel was blotted onto a sheet of 3MM 
Whatman filter paper. A piece of plastic wrap was used to cover the gel 
surface. The gel was dried in a gel dryer (BioRad Laboratories, Model 
543). Autoradiography was done to detect the sequencing bands. 
Autoradiography 
Kodak X-OMAT AR diagnostic film was used for DNA sequencing film. 
Films were exposed in a Kodak X-Omatic cassette at -70°C for one 
overnight to one week. Films were developed with Kodak X-ray 
developer for 5 minutes, fixed with Kodak X-ray fixer for 5 minutes and 
rinsed with tap water for 5 minutes. 
2.3.3 Resolving GC band compression 
If band compression occurred, Deaza T7 Sequencing Mixes (Pharmacia) 
were used instead of the standard Mix-Short provided in the T7 
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Sequencing kit (Pharmacia). Moreover, the electrophoresis was run at 
higher temperature such as 65°C. 
2.4 Overexpression of mutated Trichosanthin in Escherichia coli 
The procedure was based on Wong et al, 1994. Expression vectors 
containing mutated TCS genes were transformed into Escherichia coli 
expression host, BL21 (DE3, pLysS). Preparation of competent cells and 
transformation was performed as described in Section 2.2.6. 
A single colony of BL21 (DE3, pLysS) containing the mutated gene was 
inoculated in 5 ml M9ZB medium with 50 ug/ ml Ampicillin and 25 ug/ ml 
ChromophenicoL The culture was grown at 37°C overnight with vigorous 
shaking and then transferred to 500 ml M9ZB with the same amount of 
antibiotics. The culture was grown at 37°C with vigorous shaking until 
OD600 = 0.8 (about 4 to 5 hours). The expression was then induced by 
adding isopropyithio-p-galactoside (IPTG) to a final concentration of 0.4 
mM. The culture was grown at 37°C for 3 more hours. The cell was 
collected by centrifugation at 5,000 rpm (Hitachi High Speed Centrifuge 
SCR20B with RPR 12-2 rotor) for 10 minutes at 4°C. The supernatant 
was discarded. 
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For R29C K173C, the cell pellets were resuspended in 15 ml of 10 mM 
NaH2P04 (pH 6.5) with 0.1 mM phenylmethysulfonyl fluoride (PMSF) 
and 0.1% (v/v) p-mercaptoethanol. The suspension was sonicated for six 
cycles (30 seconds sonication and 30 seconds cooling at 4°C) and was 
then centrifliged at 21,000 g for 30 minutes at 4°C. 
2.5 Purification of modified Trichosanthin 
The method of Zhu et al, 1992 was used with modifications. The 
supernatant was applied to a CM-Sepharose CL-6B column (1.6 x 26 cm) 
equilibrated with buffer A (10 mM NaH2P04, pH 6.5). The flow rate was 
kept at 15 ml/ lir. The column was washed with buffer A until OD280 of 
the eluent was less than 0.1. TCS was eluted by applying buffer B (0.1 M 
NaCl in buffer A). The eluent was collected by fraction collector (70 
drops per fraction). OD280 of the fraction was measured. Fractions with 
OD280 greater than 0.1 were collected and pooled together and dialysed 
against buffer A. After dialysis, the eluent was filtered and was loaded to 
a Mono-S HR 5/5 FPLC column buffer (10 mM NaHzPCX pH 6.5) 
for 5 minutes. 
A O - 1 M NaCl gradient (25 ml) was applied to elute the TCS. The peaks 
were collected and analyzed by SDS-PAGE. The peak containing TCS 
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was then dialyzed against 0.01 M Tris pH 7.4, 50% glycerol which is the 
storage buffer for the purified proteins. For R29C K173C, the purification 
procedure was the same except that 5 mM NaH2P04 (pH 6.0) was used as 
buffer A and the mutated TCS was eluted from CM-sepharose column by 
0.3 M NaCl in 5 mM NaH2P(\ pH 6.0. 
2.6 Breaking of Disulphide bridge between modifled Trichosanthin 
0.6 mg of R29C TCS or R29C K173C TCS was mixed with equal volume 
of 0.1 M Tris pH 8.0, 8 ul of (3-mercaptoethanol and 25 ul of 0.5 M 
dithiothreitol were added. The reduction reaction was carried out at room 
temperature for 30 minutes. The excess p-mercaptoethanol and 
dithiothreitol were removed by dialysis against 0.01 M Tris pH 7.4. 
2.7 Coupling of DX T40 to modified Trichosanthin 
2.7.1 Activation of dextran T40 (fig.2e) 
The dextran was first derivatized to contain a bromoacetyl function (Tarn 
打 a/., 1976). In a typical preparation, 0.3 g of cyanogen bromide (Merck) 
was dissolved in 
3 ml of acetonitrile and added to 100 ml of 2% dextran T40 (molecular 
weight 40,000, from Pharmacia). pH was maintained at 10.8 for 5 minutes 
44 
by the addition of 1 M NaOH; it was then lowered to about 2.0-2.5 with 
concentrated HCl, and 2 ml of diaminoethane was added along with 
additional HCl in order to prevent the pH from exceeding 9.5; the final pH 
was adjusted to 9.5. After standing overnight at 4°C, the mixture was 
thoroughly dialyzed against distilled water. The aminoethylamino-dextran 
so obtained was dissolved in 50 ml of 0.1 M phosphate (sodium salt), pH 
7.0, and 2 ml of bromacetylbromide (Aldrich) was added through a pastern-
pipette with a finely drawn capillary tip and accompanied by vigorous 
stirring over a period of 2 hours; throughout, the pH was maintained at 7.0 
with the addition of 1 M NaOH. Afterwards, the product was lyophilized 
to yield about 1.4 g of N-bromoacetylamino-ethylamino-dextran. 
2.7.2 Coupling reaction (fig. 2f) and confirmation of completeness of 
coupling 
The coupling of mutated TCS to dextran T40 was tried at two different 
TCS/dextran molar ratios (1:25 and 1:50) and with different reaction times 
(12, 24, 48 , 72 hours). The reaction mixture was dialysed in a buffer of 
30% IM bicarbonate buffer pH 9.6 and 30 % glycerol in 0.01 M Tris. pH 
7.4. The percentage of coupling was determined by gel filtration 
chromatography on a sephadex G200 column (0.8 x 16 cm) at a flow rate 
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of O.Sml/min. 0.01 mM tris pH 7.4 was used as the elution buffer. 0.8 ml 
fractions were collected and the aborbance of each fraction at 280 nm was 
measured by spectrophotometer (Hitachi 100-10 uv-vis). The void volume 
of the column was determined by blue dextran (MW 2X10^ daltons). The 
completeness of coupling was also confirmed by SDS-PAGE using 
coomassie brilliant blue stain as described in section 2.1.1. 
2.8 Biological activities of modified Trichosanthin and Dextran-
TCS conjugates 
2.8.1 In vivo bioassay- Mid-term abortifacient activity 
Pregnant mice were raised by the University Animal House. During the 
preparation, mature female mice were caged with fertile males. The 
presence of copulation plug in the following morning is designated day 1 
of pregnancy. Assay was done by injecting various doses of TCS, mutated 
TCS or Dextran-TCS conjugates intraperitoneally into the mice at day 12 
of pregnancy. The mice were autopsied on day 14 of pregnancy. The 
total number of uterine implantation sites were recorded. The number of 
live fetuses, dead fetuses whose hearts had stopped pulsating, and 
resorbing fetuses were recorded. Mice were considered aborted when the 
number of dead fetuses exceeded 50% of the total implantation sites. 
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2.8.2 In vitro bioassays 
2.8.2.1 Ribosome-inactivating activity (Ribosome inactivating 
activity assay using rabbit reticulocyte lysate in Vitro 
translation system) 
Untreated rabbit reticulocyte lysate (Promega, L4153) was used to carry 
out in vitro translation. The method employed was modified from Keung 
et al., (1993). Master mix and working lysate were prepared as follows: 
Master Mix 
Creatine phosphate (0.8 M) 4 ul 
KCl / MgCl2 ( 2 M / 1 0 mM) 10 ul 
H2O 16 ul 
Working Lvsate 
Rabbit reticulocyte lysate (Promega) 100 ul 
H2O 100 ul 
Creatine kinase (5 mg/' ml) 2 ul 
Hemine (1 mg/ ml) 10 ul 
4 ul of master mix, 2 ul of 35S-methioiiine (Amershan SJ235, 15 mCi/ ml) 
* 
was mixed with 4 ul of sample protein (in 0.5 mg/ ml bovine serum 
albumin). 30 ul of working lysate was then added to initiate translation. 
The mixture was incubated at 30°C for exactly 30 minutes. 5 ul of the 
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reaction mixture were diluted into 1 ml of water in a 15 ml test tube. 0.5 
ml of 1 M NaOH /10% H2O2 was then added. The tube was incubated at 
37°C for 45 minutes. 1 ml ice-cold 25% trichloroacetic acid (TCA) was 
added to precipitate the translated protein and the tube was kept at 4°C for 
30 minutes, the precipitate was collected by filtration through a GF/B 
filter under suction. The filter was washed three times with 5 ml of 8% 
TCA. Finally, the filter was washed with 1 ml of acetone. After the 
acetone had been evaporated, the filter was transferred to a vial containing 
3 ml of scintillation fluid. Radioactivity was measured by liquid 
scintillation counting as described in Section 2.1.3. 
2.8.2.2 Anti-tumour activity 
The in vitro anti-tumor activity of TCS, mutated TCS and Dextran-TCS 
conjugates was assessed on 2 different cell lines, IC21 and KB 5. IC21 is a 
macrophage-like cell line derived by transformation of C57BL/6 mouse 
* 
macrophage with SV40, while H35 is a rat hepatoma cell line. IC21 and 
H35 cells were maintained in 25 cm^ culture flask in complete RPMI 
medium and complete minimal essential medium (MEM) respectively. 
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They were subcultured every 2 - 3 days after the cells almost formed 
confluent monolayer. During the subculture process, the cells that attach 
to the culture flask were trypsinized (0.25% trypsin containing 0.01% 
EDTA) for 2 - 5 minutes at 37°C. Trypsinization was stopped by addition 
of complete medium to the trypsinized cell suspension. The cells were 
washed once with complete medium. About 10^  viable cells were then 
resuspended in complete medium into the culture flask. 
In the anti-tumor assay, different concentrations of TCS, mutated TCS, 
Dextran-TCS conjugates or Bromodextran were co-cultured with 5 X 10 
tumor cells at their logarithmic phase of growth in 0.2 ml complete 
medium in the wells of a flat-bottomed 96-well microtitre plate. After 48 
hours culture, the growth inhibitory activity of the drugs on tumor cells 
was measured by ^H-Thymidine incorporation . After the culture period， 
each well was pulsed with 0.5 uCi of the labelled DNA precursor , 
[methyl-3H]thyinidine (3H-dTR) for 6 hours. The radioactivity 
incorporated was harvested by a PHD cell harvester (Cambridge Tech.) on 
a glass fiber filter. 50 ul of 0.1 M NaOH was added to each well to detach 
the adherent cells prior to the normal cell harvesting procedure. The 
radioactivity was measured by liquid scintillation counting as described in 
Section 2.1.3. 
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The direct cytotoxic effect of TCS, DX-TCS or bromodextran on 
the cultured tumor cells was also studied. 5 - 10 X tumor cells were 
incubated with the highest concentration (100 ug/ml) of TCS, DX-TCS, or 
bromodextran for 48 hours, and cell viability was assessed by using the 
trypan blue dye exclusion method. Cells which were stained blue as 
observed under the microscope were regarded as dead cells. Cytotoxicity, 
as judged by cell killing can then be evaluated. 
2.9 Immunogenicity of mutated Trichosanthin and Dextran-TCS 
conjugates 
2.9.1 Method of Immunization and bleeding 
C57 BL/ 6N inbred mice ( 6 - 8 weeks old) were used for the experiments. 
Mice in groups of five were immunized subcutaneously at the back with 
10 ug of nTCS , R29C, K173C, R29C K173C, DX-R29C, DX-K173C , 
DX-R29C K173C or dextran in vegetable oil on day 0.(the amount of the 
conjugates are equivalent to 10 ug of nTCS,while the amount of dextran is 
equal to the amount present in DX-R29C, DX-K173C or DX-R29C 
Kl73C).The booster injection was given on day 21 using the same 
antigens. The bleeding of the primed mice was carried out 7 days after the 
booster injection. Blood was collected through retrobulbar puncture 
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under light ether anesthesia. Sera from each group of mice were stored at 
-20°C until use. 
Another experiment with same immunization protocol was done for 
comparison in which adjuvant was used. Parallel groups of the same strain 
of mice were primed by the same antigen with Freund's complete adjuvant 
and booster was given in incomplete Freund's adjuvant. Moreover, 
hyperimmune mouse sera against TCS which has been characterized by 
radioimmunoassay was obtained by repeated injection of TCS. 
The experiment was also done with TCS in denatured form. The protein 
(natural TCS, mutated TCS and Dextran-TCS conjugate) were denatured 
by 0.5 % SDS at 80。C for 10 minutes before immunization. The denatured 
protein was injected with vegetable oil and the same immunization 
schedule was followed. 
2.9.2 Determination of IgG and IgE antibody levels by Enzyme 
Linked Immunosorbant Assay (Elisa) 
Specific IgG and IgE antibodies against nTCS and dextran were detected 
by conventional enzyme-linked immunosorbant assay (ELISA). ELISA 
plates (Immunoplate, Maxisorp, Nunc) were coated overnight at 4 C with 
100 ul of antigen (5 ug/ ml nTCS or 100 ug/ ml dextran) in 0.05 M sodium 
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carbonate-bicarbonate buffer (pH 9.6 with 0.1% sodium azide). On the 
following day the plates were washed three times with washing buffer 
(PBS, pH 7.2 with 0.05% v/v Tween-20) and then blocked for 1 hour at 
37°C with 200 ul/ well blocking solution (washing buffer with 1% BSA). 
After blocking, the plates were again washed, then blotted dry. Positive 
control sample, antisera (diluted with washing buffer with 0.5% BSA) 
were added, in duplicate, to the ELISA plate at 100 ul/ well. The plates 
were incubated for 1 hour at 37°C. The plates were then washed 3 times, 
followed by the addition of 100 ul detecting antibody (sheep anti-
mouse IgG-horseradish peroxidase conjugate (Serotec) or sheep anti-
mouse IgE (Serotec) and incubated for 1 hour at 37°C. After this 
incubation period, the plates were protected from light. To detect IgE, 
another 1 hour incubation period with a 3「」antibody, donkey anti-sheep 
IgG-horseradish peroxidase conjugate (Sigma) was needed before adding 
the substrate solution. The substrate solution was o-phenylenediamine 
dihydrochloride (OPD). OPD tablets (4mg/ tablet) were dissolved in 
substrate buffer (0.2 M phosphate-citrate buffer, pH 5.0) containing 0.04% 
H2O2. This solution was freshly prepared and used within 60 minutes and 
held at room temperature in dark. After 30 minutes, the reaction was 
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stopped with the addition of 50 ul 2.5 M H2SO4 and the absorbance was 
read on ELISA plate reader (Dynatech 5000) at 490 run. 
2.10 Nephrotoxicity of Trichosanthin and Dextran-TCS 
conjugates 
2.10.1 Functional study 
Sprague-Dawley rats weighing between 350 - 400 g were individually 
placed in metabolic cages. After 2 days of equilibration, single dose of 
TCS was injected peritoneally into each rat and the dosage used ranged 
from 0.03 mg/ rat to 4.8 mg/ rat (0.03, 0.3, 0.6, 2.4 and 4.8 mg). On the 
2nd and 3rd day after injection, 2 rats from each dosage group were 
anesthetized by ether and sacrificed after removal of both kidneys. Others 
were carried on in the metabolic cages for 10 days and then sacrificed. 
While the rats were in the metabolic cages, urine samples were collected 
daily and blood sample on specific days by retro bulbar puncture. Plasma 
and urine creatinine concentration were measured by a Beckman 
Creatinine Analyzer II. Sodium and potassium concentrations were 
measured by Corning Clinical Flame Photemeter. Urine protein 
concentration was determined by the Lowry method as described in 
section 2.1.2. Urine protein composition analyzed was by SDS-
Polyacrylamide gel electrophoresis. Statistical analysis was performed by 
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analysis of variance to evaluate the effect of TCS on the GFR , sodium and 
protein excretion. 
Creatinine measurement by Beckman Creatinine Analyser II 
Creatinine concentration (mg/ dL) was measured by Beckman Creatinine 
Analyzer II with Beckman Creatinine Reagent kit according to the 
instruction manual of the equipment. The method based on the formation 
of colored alkaline creatinine picrate complex between creatinine and 
picrate acid. Calibration was done using Calibration standard of 5.0 mg/ 
dL creatinine. Serum samples were measured directly while urine samples 
were diluted 20 times with distilled water before measurement. The serum 
and urine samples were freezed at -20°C if they were not measured 
immediately after collection. 
Sodium and Potassium concentration determination by Flame 
Photometry 
Sodium and potassium concentration (mM) were measured by Coming 
Clinical Flame Photometer according to supplier's instructions. Urine and 
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serum samples were diluted 200 times by diluent (prepared from diluting 
diluent Concentrate (Coming) 1000 times) before measurement. The urine 
and serum standard (Coming) were also diluted 200 times before 
calibration (Urine: Na 160 mM, K 80 mM; Serum: Na 140 mM, K 80 
mM). The potassium or sodium ion concentration can be directly read 
from the instrument. Calibration was done every 20 samples to ensure that 
the instrument was stable throughout the measurement. 
2.10.2 Morphological study 
Renal tissues were fixed in 10% buffered formalin and routinely processed 
for light microscopy. Hematoxylin and eosin, periodic acid-Schiff and 
periodic-acid silver methanamine stained sections were examined for light 
microscopy. Several 1mm renal tissue fragments were sampled and fixed 
in cold 2.5% phosphate buffered glutaraldehyde. After overnight fixation, 
the tissues were rinsed several times with phosphate buffered sucrose, and 
post-fixed with 1% osmium tetroxide. Ultrathin sections were stained with 
saturated aqueous uranyl acetate and lead citrate solutions. The sections 
were studied independently by two people in a single blinded manner. A 









1. Forward primer ofpET58210 (20 mer): pET fwd | 
AACGGTTTCCCTCTAGAAAT 
2. Primer C (18 mer): 
i 
TCCCAATTTGTTGCTCAA. 
3. Oligo R29C Forward (23 mer): PR29C fwd 
TCCAAATGAA TGC AAACTGTACG 
Cysteine 
4. Oligo R29C Reverse (23 mer) : PR29C rev 
CGTACAGTTT GCA TTCATTTGGA 
Primers used for the construction of K173C 
1. Reverse primer ofpTrc58210 (36 mer): pTrc 58210 rev 
AAGCTTGCATGCCTGCACCTCGACTCTAGAGGATCC 
2. Primer E (20 mer): 
CAAACTGCTGCAGGCAAAAT 
3. Oligo K173C Forward (23 mer) : PK173C fwd 
ACAAATTGGG TGC CGTGTTGACA 
cysteine 
4. Oligo K173C Reverse (23 mer) : PK173C rev 
TGTCAACACG GCA CCCAATTTGTC 
Figure 2a : Primers used in polymerase chain reactions 
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Figure 2b : PGR and subcloning of R29C mutant (sizes ofplasmids not to 
scale). 
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Figure 2e : Activation reaction of dextran T40. 
59 . 
H H H H H ^ ^ II I I I I I , X 
r— O - C - NH-C-C-N-C-C—Br uc 广 、 
Dextran A A M HS — ^ C S J 
OH \ ^ ^ ^乂 
NH, H H H H H 
‘ II • I I I I F \ 
O—C— NH-C-C-N-C-C —s _ ( TCS 
Dextran H H HH 
OH 
Figure 2f : Coupling reaction of activated dextran (bromoacetyl dextran)to 
modified Trichosanthin. 
Chapter 3 Construction of TCS mutants 
3.1 Introduction 
In order to introduce sulphydryl group/cysteine residue to specific site 
of TCS molecule , site-directed mutagenesis was carried out on the 
plasmid pET 58210 (the plasmid that housed the TCS cDNA) to give 
three mutated plasmids : pET R29C, pET K173C and pET R29C 
K173C. The plasmids are ready for expression to give modified TCS 
proteins which can be coupled to dextran T40. 
3.2 Method 
The method was described in sections 2.2.12, 2.2.13 and 2.2.14. 
Polymerase chain reaction (PCR) using overlapping primer method was 
employed to carry out the mutagenesis. The PCR fragments containing 
the mutations were subcloned into expression vector pET 8c. Mutated 
plasmids were screened by their size, restriction patterns and DNA 
sequences. Entire portion of DNA sequence synthesized by PCR was 
sequenced to ensure there was no second site mutation. The R29C 




3.3.1Construction of K173C 
PCR and subcloning 
The strategy of construction is shown in Fig.2a and the methods are 
described in Section 2.2.13. PCR was carried out as described in 
Section 2.2.9. The PCR products were loaded to a 1% agarose gel. 
After electrophoresis, DNA fragments of 0.15 and 0.23 kb were 
obtained as expected (Fig. 3a). The two fragments were purified by 
GeneClean II® kit (Section 2.2.8). The second PCR product (0.35 kb 
fragment) was also separated by 1 % agarose gel electrophoresis (Fig. 
3b). After digestion with Pst I and BamH I (Fig. 3c, lane 2)，the 0.35 
kb fragments were ligated to the 4.6 kb fragment of pET 8c (Fig. 3c, 
lane 1) and 0.4 kb fragments of pET 58210 (Nco I and Pst I cut) 




Screening of mutant 
Ligation of the 0.35 kb PGR fragment, 0.34 kb and 4.6 kb of pET8c 
fragments should give a plasmid of similar size to pET58210. The 
transformed plasmids were screened firstly by their sizes. The plasmids 
from transformed colonies were isolated by minipreparation (Section 
2.2.3). The size of the plasmids were analysed by 0.8% agarose gel 
electrophoresis (Fig. 3.d). By comparing the sizes of the plasmids with 
a pET 58210 marker, colony number 6 appeared to be the mutated 
clones. 
Restriction digestion of plasmid from transformants 
In order to facilitate restriction digestion and subsequent DNA 
sequencing, plasmid of colony number 6 was isolated to higher purity 
by Qiagen cartridge (Section 2.2.4). The purified plasmid was digested 
separately with two pairs of restriction enzymes(Pst I and BamH I, Pst 
I and Nco I) and products separated by 1% agarose gel electrophoresis. 
As shown in Fig. 3e, digestion of the plasmid give the correct size 
fragments (0.35 kb and 0.4 kb respectively). Hence, the selected clone 




DNA sequencing was perfoimed by Sanger's method as described in 
section 2.3. The result of DNA sequencing concerning the mutated sites 
of TCS were shown in Fig. 3f. It was shown that AAG codon of 
lysine-173 was mutated to TGC (encoding cysteine). 
3.3.2. Construction of R29C mutant 
The strategy of construction is shown in Fig.2b and the method is 
' desc r i bed in section 2.2.13. PCR was carried out as described in 
section 2.2.9. 
0.12 kb and 0.45 kb fragments were obtained (Fig. 3g) from first PCR. 
The second PCR gave a 0.57 kb fragment (Fig. 3h), which was cut with 
Nco I and Pst I to give a 0.4 kb fragment. The 0.4 kb fragment was 
ligated to the 4.6 kb fragment ofpET 8c (Fig. 3j, lane 3) and 0.35 kb 
fragment of pET58210 (BamH I and Pst I cut) (Fig. 3j, lane 1). 
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Screening of mutant 
Plasmids from transformed colony were screened firstly by size (fig. 
3k). Colonies 1, 3, 5, 6, 8, 9，10, 11 and 12 has the same size as pET 
58210. Colonies 1, 6, 11，12 were further screened by restriction 
enzyme digestions (fig. 3e). Sal I digestion should give a small 
fragment of 0.8 kb, while BamH I and Nco I should cut out a 0.7 kb 
fragment. All the selected clones may contain the mutated gene. The 
mutation was confirmed by DNA sequencing and all 4 clones contained 
the desired mutation. Fig. 3m showed the result of DNA sequencing of 
colony 6. The AGG codon of arginine 29 was mutated to TGC 
(encoding cysteine). 
3.3.3 Construction of R29C K173C double mutant 
The strategy of construction is shown in Fig.2c and the method is 
described in section 2.2.14. pET R29C was cut with Ncol and Pst I to 
give 0.35 kb fragment (Fig. 3o), while pET K173C was cut with BamH 
I and Pst I to give 0.4 kb fragment. (Fig. 3p). The two fragments were 
ligated to the 4.6 kb fragment ofpET 8C (Nco I and BamH I cut). The 
ligated DNA was transformed into Escherichia Coli strain DH5a. 
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Screening of mutant 
The colonies were screened by size (fig 3q). 3 colonies got the correct 
sizes. The mutation was further confirmed by DNA sequencing (fig. 3r) 
3.4 Discussion 
Mutation of TCS cDNA was performed by PCR mutagenesis using 
overlapping primers method. The PCR method is an effective way of 
site-directed mutagenesis. Double stranded DNA can be used as 
template, so expression vector with TCS cDNA (pTrc 58210, pET 
58210) can be used directly as template. No subcloning procedure and 
purification of single stranded template is required. PCR also amplifies 
the mutated fragment of DNA to give sufficient amount of DNA for 
subcloning. As all the PCR fragments produced should contain the 
mutation, the screening process is greatly simplified. 
However, PCR mutagenesis has one drawback: the requirement 
of restriction sites near the mutation site for subsequent subcloning of 
the PCR fragment. Unfortunately, for both R29C and K173C mutants 
，there are no convenient restriction site near the mutation sites. This 
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problem was overcomed by using the overlapping primer method for 
PCR mutagenesis. (Fig.3s). 
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Figure 3s. Site-directed mutagenesis by overlapping primer method. 
On separate PCRs, two fragments of the target gene sequence are 
amplified. Each reaction uses one flanking primer that hybridizes at 
one end of the target sequence (primer a or d) and one internal primer 
that hybridizes at the site of the mutation (primer b or c) and contains 
the mismatched bases. As the two internal primers have overlap, the 
two fragments AB and CD generated in the first PCR can be fused by 
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denaturing and annealing them in a subsequent primer extension 
reaction. The overlap allows one strand from each fragment to act as a 
primer on the other, and extension of this overlap results in the mutant 
product. The fusion product formed can then be amplified by second 
PCR with the two flanking primers. By this method, the mutation can 
be far away from the restriction sites used for subsequent subcloning 
(restriction sites (1) and (2)). 
In the construction of R29C and K173C mutants, a Pst I site was 
included on one of the flanking primer. However, Pst I site is not a 
unique site of pET 58210 plasmid, therefore a two-fragment ligation is 
not possible in subsequent subcloning, as the pET 58210 will be cut at 
more than one site. A three-fragment ligation was used instead. For 
the R29C K173C double mutant, as there is a Pst I site between the 
two mutation sites, the double mutant was easily constructed by 
subcloning of the two single mutants, R29C and kl73C, using three-
fragment ligation again. 
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Figure 3a : Agarose gel analysis of first PCR of K173C mutation 
Lane 1 : product of PCR using PK173Cfwd and pTrcrev 
as primers (arrow) 
Lane M : 123 bp ladder marker 
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* Figure 3b : Agarose gel analysis of second PCR o f K l 73C mutation 
Lane 1 : second PCR product (using Primer E and 
pTrc rev as primers) (arrow) 
Lane M : 123 bp ladder marker 
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Figure 3c : Agarose gel analysis of restriction enzyme digestion 
Lane 1 : pET 8C cut with BamHI and Nco I 
Lane 2 : second PGR product cut with Pst I and BamHI 
Lane M : 123 bp ladder marker 
Lane 3 : pET58210 cut with Nco I and Pst I 
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Figure 3d ： screening of transformed colonies 
Lane 1-2，3-4, 7-9 : colony no. 1-7 
Lane 3 : pET8C uncut 
Lane 6 : pET58210 uncut 
Lane M : X- Hind III digested marker 
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Figure 3e : Restriction digestion of plasmid from tranformed colonies. 
‘ Lane 1 : colony 6 plasmid cut with BamHI and Pst I 
Lane M : 123 bp ladder marker. 
Lane 2 : colony 6 plasmid cut with Pst I and Nco I 
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Figure 3f : Confirmation of K173C mutation by DNA sequencing. 








Figure 3g : Agarose gel analysis of first PCR products. 
Lane 1 : product of PCR using pET fwd and PR29C rev as 
primers, (arrow) 
Lane 2 : product of PCR using Primer C and PR29C fwd as 
‘ primers, (arrow) 
Lane M :X -Hind III digested marker. 
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• Figure 3h : Agarose gel analysis of second PCR product 
Lane 1: product of second PCR using pET fwd and Primer 
C as primers, (arrow) 
Lane 2 : pET 58210 uncut 
Lane M : 123 bp ladder marker. 




Figure 3 i : Agarose gel analysis of restriction enzyme digestion of 
second PCR product. 
Lane 1: second PCR product digested with Nco I and Pst I 
Lane M : X-Hind III digested marker (arrow) 
* 
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Figure 3j : Agarose gel analysis of restriction enzyme digestion 
Lane 1 : pET 58210 cut with BamHI and Pst I 
Lane M :人-Hind III digested marker 
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Figure 3k : Screening of transformed colonies of R29C 
Lane 1-12: colony 1-12 
Lane M : Hind III digested marker 
LaneN : pET58210 (uncut) 
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Figure 31: Restriction digestion of transformed colonies of R29C 
Lane 1 : colony 1 digested with Sal I 
Lane 2 : colony 6 digested with Sal I 
Lane 3 : colony 6 digested with BamHI and Ncol 
Lane 4 : colony 11 digested with Sal I 
Lane 5 : colony 12 digested with BamHI and Ncol 
Lane 6 : colony 12 digested with Sal I 
Lane 7 : pET 58210 digested with Sal I 
Lane M : 123 bp ladder marker 
Lane N : X-Hind III digested marker 
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Figure 3 m : Confirmation of R29C mutation by DNA sequencing 
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Figure 3n : Agarose gel analysis of restriction digestion of pET R29C 
Lane 1: pET R29C digested with Ncol and PstI 




、 Figure 3o : Agarose gel analysis of restriction digestion of pE TK173C 
Lane 1 : pETK173C cut with BamHI and PstI 






Figure 3p : Screening of transformed colonies of double mutant 
Lane 1-5，8-14 : Colony 1-12 
Lane 6 : pET8C (uncut) 
Lane 7 pET58210 (uncut) 
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Figure 3q : Confirmation of R29C K173C double mutation by DNA 
sequencing 
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Figure 3q : Confirmation of R29C K173C double mutation by DNA 
sequencing 
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Chapter 4 Expression and Purification of modified 
TCS proteins 
4.1 Introduction 
The three modified TCS proteins (R29C, K173C and R29C K173C) 
must be expressed and purified before they can be coupled to dextran. 
Expression of protein was performed in E. coli. However, the 
expressed protein was impure due to the presence of large amount of 
unwanted proteins from the bacterial cells. Modified TCS protein was 
separated from the unwanted proteins by ion exchange chromatography 
which made use of the very basic nature of TCS . 
4.2 Method 
The method of Zhu et al” 1992 was used with modifications and was 
described in sections 2.4 and 2.5. Plasmids with the mutated TCS 
cDNA were transformed into expression host Escherichia coli BL21 
(DE3, plys S). Isopropylthio-P-galactoside (IPTG) was added to 
induce protein expression. The bacteria were lysed by sonication. 
CM-sepharose CL-6B cation exchange chromatography and Mono-S 
Fast Protein Liquid Chromatography (FPLC) were employed to purify 
the proteins in the cytoplasmic fractions of the cells. The purified 
proteins were analysed by SDS-PAGE and characterised by ribosome-
inactivation assay. 
In ribosome-inactivation assay ,untreated rabbit reticulocyte lysate 
was used to carry out in vitro translation. The method employed was 
modified from Keung el ar.(1993) (section 2.8.2.1).Briefly, the TCS 
protein samples was added to the reagent mixture of the in vitro 
translation system with S-35 methionine as the radioactive label of 
translated proteins . The translated proteins were then precipitated by 
25% Trichloroacetic acid and was filtered. The radioactivity of the 
precipitate was measured by liquid scintillation counting as described in 
section 2.1.3. 
4.3 Results 
4.3.1. Expression , puritication and ribosome-inactivating 
activity of R29C 
Method described in section 2.4 and 2.5 was followed. 1000 ml 
bacterial culture was grown for expression of R29C. After sonication 
and centrifiigation, the supernatant was loaded onto CM-sepharose CL-
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6B column (1.5 cm x 16 cm). The column was washed with buffer A 
(lOmM NaffiP04, pH 6.5) until OD280 of the eluent decreased below 
0.1. The modified TCS protein was eluted out by buffer B (0.1 M 
NaCl in buffer A). The elution profiles was shown in Fig.4a (Fraction 
size: 70 drops per tube). Fractions 12 - 16 were pooled together and 
dialysed against buffer A. The protein was then further purified by 
Mono S HR 5/5 FPLC column. Fig. 4b showed the elution profile and 
the chromatographic conditions. R29C was eluted at NaCl 
concentration of 0.13 M The results of each step of purification was 
analysed by SDS-PAGE(Fig.4c). The ribosome-inactivating activity of 
R29C was shown in Fig.4d . The modified TCS protein got the same 
activity as nTCS ,with an ID50 of 3 ng/ ml. 
4.3.2. Expression，purification and ribosome-inactivating activity 
ofK173C 
The same procedures and reagents as purification of R29C was used. 
K173C was successfully expressed in E. coli. The elution profile from 
CM-sepharose by buffer B was shown in Fig.4e . Fraction 10 -12 was 
dialysed and then further purified by FPLC (Fig.4f). Fig.4g shows the 
SDS-PAGE gel showing the expression of K173C in E. coli. The 
results of purification by CM-sepharose and FPLC were shown in 
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Fig.4h and 4 i . The K173C was eluted at NaCl concentration of 0.1 M 
in FPLC. The modified TCS protein got the same activity as nTCS 
(Fig.4j ). 
4.3.3. Expression , purification and ribosome-inactivating activity 
ofR29C K173C 
Similar procedure as for purification of R29C or K173C was followed 
but with some modifications in the conditions. Buffer A was 
changed to 5 mM NaH2P04 pH 6.0 and the modified TCS protein was 
eluted out from CM-sepharose column by 0.3 M NaCl in 5 mM 
NaHJPCX pH 6.0 (Fig.4k). Fractions 15 - 18 were dialysed against 5 
mM NaHzPCX pH 6.0. After dialysis, the protein was further purified 
by Mono S HR5/5 FPLC column (Fig.41). The equilibrating buffer for 
FPLC column was also changed to 5 mM NaHJ^CX, pH 6.0. The 
modified TCS protein was eluted at salt concentration of 0.13 M in 
FPLC. The results of purification were shown in Fig.4m (SDS-PAGE 
gel). ‘ The ribosome-inactivating activity of the R29C K173C was 
slightly lower (p<0.05) than that of nTCS，with an ID50 of 10.0 7.3 
ng/ ml (Fig.4n). 
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4.4 Discussion 
pET vector system (Studier et al 1990) was employed to express 
three mutated TCS cDNA in E. coli . The vector pET 8c contains the 
T7 (|)10 promoter and (j) terminator. The TCS cDNA was cloned into 
pET 8c at the Nco I and BamH I site to form pET 58210. The TCS 
cDNA was expressed in specific expression host - E. coli BL 21 (DE 3, 
plys S). The expression of TCS can be switched on by the addition of 
EPTG at the right time by the following mechanism. The T7 (j) 10 
promoter was not recognized by bacterial RNA polymerase but by 
bacteriophage T7 RNA polymerase. The expression host BL21 (DE3, 
plys S) used is a lysogen harbouring the bacteriophage T7 RNA 
polymerase gene under the control of lac UV5 promoter. ‘ Upon 
induction of IPTG, T7 RNA polymerase is expressed ,which in turn 
switches on the T7 (j) promoter and therefore the expression of TCS 
cDNA. Before addition of DPTG, basal level expression of TCS cDNA 
was suppressed by the T7 lyzoyme, encoded by the plasmid plys S of 
the expression host BL21 (DE3, plys S). Another function of T7 
lyzoz3^e was to lyse the bacterial cells, so that a simple freeze and 
thaw was enough to release the intracellular T7 lyzozyme and lyse the 
cells. Sonication was done to ensure complete breakage of cells. 
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Majority of the expressed protein was present in the inclusion bodies of 
the E. coli (Zhu et al, 1992). However, the solubilization of protein 
require a much more tedious procedure, and substantial amount of 
proteins was already obtained from the soluble cytoplasmic fractions. 
Therefore, only protein in soluble fractions was purified, and the yield 
was around 10 mg protein per litre of E. coli culture. 
The modified TCS proteins in the soluble fractions were purified by a 
two-step purification that based on Zhu et a/.(1992) with modifications. 
The method made use of the very basic nature of TCS which binds to 
cation exchange column. However, the modified TCS proteins 
produced in the present study has mutated positively charged amino 
acids that are located on the surface of the molecule (positively 
charged lysine / arginine to neutral cysteine). The modified TCS 
proteins, especially R29CK173C, obviously bind less efficiently to 
cation exchange than nTCS, therefore a lower salt concentration was 
used in the equilibration and elution buffers. For R29C K173C, even 
the pH of the equilibration buffer has to be changed. On the contrary, 
mutations inside the core of the protein do not change the charge 
properties of the protein (Wong et al, 1994). 
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CM-Sepharose CL-6B cation exchange chromatography was aimed at 
removing majority of impurities from crude bacterial lysates. (Fig.4m 
lane 3). The modified TCS proteins were ftirther purified by Mono S 
cation exchange FPLC. A salt gradient of 0 - 1 M NaCl was used to 
elute the modified TCS protein. 
The modified TCS protein was purified to homogeneity as indicated by 
a single band in SDS-PAGE and single peak in FPLC. The modified 
TCS protein also has the same size as nTCS in SDS-PAGE. The 
ribosome-inactivating activity of R29C and K173C was the same as 
nTCS. Ribosome-inactivation is the characteristic activity of TCS. The 
activity of R29C K173C was slightly lower than nTCS as the 
modification of two surface amino acids might change the conformation 
of the protein slightly, affecting its activity. From the molecular sizes 
in SDS-PAGE , the ribosome-inactivating activities and previous 
confirmation of TCS gene sequence by DNA sequencing, the purified 
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Figure 4b : Elution profile of R29C from Mono S FPLC column 
Volume of sample injected : 2 ml 
Buffer A : lOmM NaH2P04 pH 6.5 
Buffer B : 0.1 M NaCl in Buffer A 
Flow rate : 1 ml/ min 
Gradient: 0.5 min ( 0% B，100% A) 
- 5 - 65 min (0% to 100% B，linear gradient) 
65 -70 min (100% B) 
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Figure 4c : Purification of R29C as analysed by SDS-PAGE 
Lane 1 : Pellet of crude bacterial lysate after 
centrifugation 
Lane 2 : Supernatant of crude bacterial lysate after 
centrifuaation 
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Lane 3-4 : Eluent during washing of CM-sepharose 
column by Buffer A 
Lane 5-6 : CM-sepharose eluent of R29C mutant 
Lane 7 : Mono S eluent of R29C mutant 
Lane N : nTCS 
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Figure 4e : Elution profile of K173C from CM-Sepharose Column 
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Figure 4 f : Elution profile of K173C from Mono S FPLC column 
Volume of sample injected : 2 ml 
Buffer A : lOmM NaH2P04 pH 6.5 
Buffer B : 0.1 M NaCl in Buffer A 
Flow rate : 1 ml/ min 
Gradient: 0.5 min ( 0% B, 100% A) 
5 - 65 min (0% to 100% B，linear gradient) 
‘ 65 -70 min (100% B) 
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Figure 4g ： Expression of K173C as shown by SDS-PAGE 
Lane 1-3 : Crude bacterial lysate of K173C 
Lane M : Low molecular weight marker 
LaneN: nTCS 
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Figure 4h : Purification of K173C by CM-sppharose 
Lane 1-2 : Eluent during washig of CM-sepharose 
column by Buffer A 
Lane 3-4 : CM-sepharose eluent (fraction 23 and 25) 
Lane 7-8 : CM-sepharose eluent (fraction 11 and 17) 
Lane M : Low molecular weight marker 
Lane N : nTCS ^ 
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Figure 4 i : Purification of K173C by Mono S FPLC 
Lane 1 : Mono S eluent of K173C mutant 
Lane M : Low molecular weight marker 
, Lane N : nTCS 
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Figure 4k : Elution profile of R29C K173C from CM-sepharose column 
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Figure 41: Elution profile of R29C K173C from Mono S FPLC 
column 
Volume of sample injected : 2 ml 
Buffer A : 5mM NaH2P04 pH 6.0 
Buffer B : 0.1 M NaCl in Buffer A 
Flow rate : 1 ml/ min 
Gradient: 0.5 min ( 0% B，100% A) 
5 - 65 min (0% to 100% B, linear gradient) 
65 -70 min (100% B) 
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Figure 4m : Purification of R29C K173C as analysed by SDS-PAGE 
Lane 1-2 : Crude bacterial Ivsate 
Lane 3 : CM-sepharose eluent of double mutant 
Lane 4 : Mono S eluent of double mutant 
Lane N : nTCS 
Lane M : Low molecular weight marker 
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Figure 4n : Ribosome-inactivation assay of R29C K173C 
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Chapter 5 Coupling of Dextran T40 to mutated 
Trichosanthin 
5.1 Introduction 
TCS is a small molecular weight protein which lost easily through 
filtration in kidney. It was also found to be nephrotoxic upon acute 
infusion (Ko et al 1994). The allergenicity of the protein also limits 
its multiple infusion (Ng et al, 1992, Xu et cd, 1992). Ko et al., (1992) 
has successfully reduced the allergenicity of TCS by coupling TCS to 
dextran T40 using dialdehyde method. However, the biological 
activities were also diminished dramatically. This may be due to the 
blocking of active site of TCS by the dextran molecule. In the present 
study, using another method of coupling, dextran was coupled to TCS 
at specific sites which are potential antigenic epitopes but not close to 
the active site of TCS. 
Alkylation method of coupling was used (section 2.7). This method 
couples dextran only to sulphydryl group, i.e. cysteine residue created 
by site-directed mutagenesis of TCS. The cysteine residues were 
located at suspected antigenic eptitopes of TCS. As there is no 





The alkylation method (Tain et al, 1976) was used for the coupling of 
modified trichosanthin to dextran T40 (section 2.7). The method 
involves the activation of dextran hydroxyl group with cyanogen 
bromide (CNBr) and then derivatization of dextran to form bromoacetyl 
function ,which in turn linked to the sulphydryl group of modified TCS 
protein. During coupling, two different TCS to dextran molar ratio 
(1:25 and 1:50) ,and different reaction time (12,24,48,60,72 hours) 
were done, in order to find out an optimum reaction condition for the 
coupling reaction. Successful coupling was confirmed by gel-filtration 
chromatography and SDS-PAGE. 
5.3 Results 
5.3.1. Coupling of R29C 
It was found that R29C gave an extra band with molecular weight of 
approximately 52 kDal (2 times that of nTCS or modified TCS protein) 
(Fig. 5a, lane 2,3) when it was concentrated and stored in 0.01 M Tris 
pH 7.4 with 50 % glycerol. It was suspected to be a dimer formed by 
a disulphide linkage between two R29C molecules. Therefore, in order 
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to get successful coupling, the disulphide bridge must be broken. This 
was done by reduction with dithiothreitol and P -mercaptoethanol as 
described in Section 2.6. The result was shown in Fig. 5a, lane 4. 
The coupling was carried out at various reaction time (12, 24, 48, 60, 
72 hours) (fig.5b-5e). A 48 hour reaction gave complete coupling of 
dextran T40 to modified TCS protein. A molar ratio of 1 : 50 (TCS : 
Dextran) was the lowest ratio that resulted in complete coupling. 1 : 25 
ratio gave just about 40% coupling (fig.5f). After coupling to dextran, 
TCS was eluted out faster on Sephadex G200 Column (standardized by 
blue dextran) (Fig. 5g), as molecular weight of the protein increased 
drastically from 26,000 to 66,000. Therefore, the coupling of dextran to 
TCS for subsequent experiment was done at molar ratio of 1 : 50 (TCS 
¥ 
:Dextran) for 48 hours. SDS-PAGE also revealed successfully 
coupling of dextran to R29C (Fig. 5m, lane 1 and 2). The DX-R29C 
conjugate has a continuous range of molecular weight which was over 
66 kDal. 
A control experiment has been performed to verify that the bromoacetyl 
dextran can couple only to sulphydryl group of TCS. The same 
coupling reaction was performed with nTCS (without cysteine residue). 
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The results indicated that there was no increase in molecular weight of 
TCS ,and thus no coupling occurred. (Fig. 5h). 
5.3.2. Coupling ofK173C 
The same coupling procedure as R29C was used (48 hour reactions, 1 : 
50 TCS to DX molar ratio). No dimerization was found. The 
completeness of coupling was also confirmed by Sephadex G200 
column and SDS-PAGE. (Fig. 5i, 51, lane 1, 2). Complete coupling 
was achieved. 
5.3.3. Coupling of R29C K173C 
The same procedure as R29C was followed. As in R29C , dimerization 
occurred again. The dimer was also broken up up by DTT and p -
mercaptoethanol (fig.Sj). Sephadex G200 column and SDS-PAGE 
indicated complete coupling of DX T40 to modified TCS protein (Fig. 
5k, 5in). 
5.4. Discussion 
The alkylation method is a convenient and effective way of coupling 
dextran to protein bearing sulphydryl group(s). The 
bromoacetyldextran derivative, i f lyophilized, can be stored at -20°C 
for long period of time before coupling, so a large amount of dextran 
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can be activated at one time. When coupling is required, the activated 
dextran can react with modified TCS protein easily to give the 
conjugate. 
The most critical step during the derivatization / activation of dextran 
was the reaction of bromoacetyl bromide with aminodextran derivative. 
The pasteur pipette used for the addition of bromoacetyl bromide to the 
reaction mixture must get a very fine outlet, so that very fine droplets of 
bromoacetyl bromide were generated. The fine droplets allowed a large 
surface area for the chemical reaction to take place. 
Different reaction conditions (reaction time and molar ratio of 
reactants) were tried in the coupling reactions, in order to achieve an 
optimum condition for complete coupling . The reaction was best 
performed at TCS to DX molar ratio of 1 : 50 for 48 hours. The 
completeness of coupling increased with reaction time up to 48 hours 
and then decreased. This was probably due to the breaking up of 
chemical bonds between TCS and dextran in very alkaline reaction 
condition (pH=9.5). 
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The inability of Bromoacetyldextran to couple to nTCS implied that the 
bromoacetyldextran can only be coupled to sulphydryl group of a 
protein ,and therefore coupling of dextran to modified TCS protein by 
alkylation method must be site-specific 
From the result of Sephadex G200 column and SDS-PAGE, all the 
three DX-TCS conjugates had a broad range of molecular weights . 
This is due to the fact that dextran is a heterologous substance with a 
range of molecular weights. The dextran T40 preparation (Pharmacia) 
is actually a mixture of dextran molecules of molecular weights ranging 
from about 20 to 70 kDal in a normal distribution, with an average 
molecular weight of 40 kDal 
r 
From SDS-PAGE, the molecular weights of the conjugates range from 
about 67 kDal to over 94 kDal. However, The molecular weights of the 
conjugates should be around 66 kDal, as there was only one cysteine / 
sulphydryl group introduced in the modified TCS protein (R29C or 
K173C) and therefore, only one dextran molecule can be coupled to 
modified TCS protein molecule. The apparently high molecular weights 
of the conjugates can be explained by the floppy or highly branched 
nature of dextran molecules (Aspinall, 1983) ,which moved slower 
than globular protein molecules during electrophoresis. Another 
possibility is that the bromoacetyldextran might contain more than one 
reactive groups, thus more than one TCS molecules might have coupled 
to the same dextran molecule. It is also possible that the dextran T40 
sample is not a good preparation with average molecular weights higher 
than 40 kDal. 
The first explanation seems to be more reasonable as the conjugates 
eluted out in Sephadex G200 column at a position not far away from 
uncoupled TCS，and was not at the void volume of the column (as 
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Lane 1 : DX-K173C 
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Figure 5d : Coupling of R29C(48 hour reaction with TCS:DX=1:50) 
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Figure 5g : Standardization of Sephadex G200 column by blue dextran 
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Figure 5i: coupling of K173C (Sephadex G200 column elution profile) 
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Figure 5j ： Break of dimer -of R29C K173C 
Lane 1 : R29C K173C (in 50% glycerol 0.01 M Tris 
pH 7.4) 
Lane 2 : R29C K173C after treatment with DTT and 
3-meraptoethanol 
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Figure 51: SDS-PAGE analysis of coupling of K173C 
Lane 1-2: DX-K173C 
Lane N : n lCS 
Lane M : Low molecular weight marker 
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Lane 1-2 : DX-R29C 
Lane N : nTCS 
Lane M : Low molecular weight marker 
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Chapter 6 Biological Activities of Modified 
Trichosanthin and Dextran-modified 
Trichosanthin conjugates 
6.1 Introduction 
Dextran T40 was coupled successfully to modified TCS protein at 
potential antigenic sites as described in the last chapter. As the 
coupling sites were not closed to the active site cleft of TCS, the 
dextran molecule should not block the binding of substrate to the 
active site. Therefore, the effect of coupling on the biological 
activities should be minimal. In order to check whether this is true, 
different bioassays (both in vivo and in vitro), were performed to 
evaluate the biological activities of the conjugates. 
6.2 Method 
For in vivo bioassay, the mid-term abortifacient activity on pregnant 
ICR mice was selected(section 2.8.1). Two in vitro bioassays were 
performed. The first one is ribosome-inactivating activity (section 
2.8.2.1) which is the characteristic activity of TCS . The second one 
is anti-tumour activity on two different tumour cell lines (IC21 and 
H35) (section 2.8.2.2). The DX-R29C and DX-K173C conjugates 
were synthesized as described in the last chapter and section 2.7.2. 
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The conjugates has been purified by running through G200 gel 
filtration column before the biological assays. 
Briefly, the assay of mid term abortifacient activity was performed by 
administration of different concentrations (0.005-0.1 mg/25g B.W.) of 
nTCS, R29C, K173C, DX-R29C and DX-K173C intraperitoneally 
into ICR mice on day 12 of pregnancy (PD12). Mice were then 
autopsied on day 14 (PD14) of pregnancy and the abortifacient effect 
was evaluated. Control mice were injected either with normal saline 
solution or bromodextran solution. The procedure of ribosome 
inactivation assay using rabbit reticulocyte lysate in vitro translation 
system was described in section 2.8.2.1. In the assay of anti-tumour 
activity, the tumour cells (H35 or IC21) were incubated with various 
concentrations of nTCS, R29C, K173C, DX-R29C , DX-K173C and 
bromodextran (amount equivalent to that present in conjugates). The 
degree of cell proliferation was then measured by determining the rate 
of tritiated thymidine incorporated into DNA. Results were expressed 
as % inhibition with reference to the control using the formula: 
% inhibition =(1- ^H-TdR incorporation in presence of drug/^H-TdR 
incorporation in the absence of drug) X 100% 
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One way analysis of variance followed by Scheffe multiple 
comparison test was used to examine the ribosome-inactivating 
activity and the anti-tumour activities of various drugs with significant 
level o fp<0.05. 
The protein concentrations were determined by method of Lowry 
(1952) as described in section 2.1.2. 
6.3. Results 
6.3.1. In vivo biological activity- Mid-term Abortifacient Activity 
(Table 6a - 6f). 
The method was described in Section 2.8.1. In this assay for 
abortifacient activity, mice were considered aborted when the number 
of dead fetuses exceeded 50% of the total implantation sites. 
Results showed that modified TCS protein has the same potency as 
nTCS. The lowest dose that caused 100% abortion of mice was 0.02 
mg/ 25 g of body weight (B.W.) for both nTCS and modified TCS 
protein (R29C and K173C) (Table 6a, 6b and 6c). 
The reduction in abortive action after coupling dextran T40 to 
modified TCS protein was small. The lowest dose that caused 100% 
abortion was 0.05 mg/ 25 g B.W. for both DX-K173C and DX-R29C. 
(Table 6d and 6e) 
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Injection of saline, dextran or bromoacetyldextran has no abortifacient 
effect (Table 6f). 
6.2.2. In vitro bioassays 
a. Ribosome-inactivation assay 
The method was described in 2.8.2.1. The ribosome-inactivating 
activity was assayed by cell-free translation system using rabbit 
reticulocyte lysate as a source of ribosome, mRNA and other 
endogenous factors for translation. 
100% of translation (or S-35 methionine uptake) was defined by the 
radioactive count of the control (with BSA instead of sample), 
assuming that BSA does not inhibit protein synthesis. The K)50 were 
i 
expressed as means 士 SEM. 
The result for DX-R29C was shown in Fig. 6a. R29C got the same 
activity (p<0.05) as nTCS (ID50= 3土0.36 ng/ml). The activity of 
DX-R29C conjugate was lower (p<0.05) (about 20 times) than nTCS 
or R29C, with an ID50 of 60±12 ng/ ml. Digestion of dextran moiety 
restored the activity of the conjugate. The presence of dextranase or 
uncoupled dextran T40 has no effect on the ribosome-inactivating 
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activity of TCS. K173C also has the same activity as nTCS (p<0.05). 
DX-K173C is also 20 times less active than nTCS or K173C 
(p<0.05), with a ID50 of 60士4 ng/ ml (Fig. 6b). The R29CK173C , 
with ID50 of 10土7.3 ng/ ml, was slightly less active (p<0.05) that 
nTCS. The DX-R29C K173C conjugate was 20 times less active than 
the R29C K173C (p<0.05). The ID50 was 200士32 ng/ ml (Fig. 6c). 
The ribosome-inactivating activity of DX-TCS conjugate synthesized 
by dialdehyde method (Ko et aL, 1991),with an ID50 of 600±23 
ng/ml, was lower than the above three conjugates (p<0.05) (fig. 6b). 
b. Anti-tumor activity 
The cytostatic effect of DX-R29C, R29C ,iiTCS and 
bromoacetyldextran on hepatoma cell line (H35) was shown in Fig. 
6d. There was a dose dependent inhibition of the drug on proliferation 
of the cells. The activity of R29C ( ID50 = 6.0士0.4 ug/ ml) was not 
significantly different from nTCS (ID50 = 10.0±2.1 ug/ml), while DX-
R29C was significantly less active (p<0.05) than nTCS / R29C. The 
ID50 was 50.0士5.3 ug/ ml. Bromoacetyldextran also has cytostatic 
effect on heptoma cell. 
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The result of DX-K173C was shown in Fig. 6e. There was no 
significant difference (p<0.05) between the activities of nTCS and 
K173C, which has ID50 of 10.0±2.1 ug/ ml and 12.0士 1.5 ug/ ml 
respectively. The activity of DX-K173C conjugate was significantly 
lower (p<0.05) than nTCS or K173C, with an ID50 of 30.0士5.9 ug/ 
ml. 
Figure 6f and 6g showed the anti-tumour activity of DX-R29C and 
DX- K173C on IC21 respectively. R29C showed significant 
difference (p<0.05) in activity from nTCS while K173C was not less 
active (statistically non-significant at p<0.05) than nTCS. The ID50 
of nTCS, K173C and R29C were 5.0士 1.4 ug/ ml, 9士 1.3 ug/ ml and 
20士5.6 ug/ ml respectively. DX-K173C and DX-R29C were both 
significantly less active than nTCS (p<0.05), with ID50 of 50.0士2.9 
ug/ml and 60.0±4.6 ng/ml respectively. However, bromoacetyldextran 
also possessed similar cytostatic effect on IC21 as the conjugate. 
6.3 Discussion 
The biological activities of TCS both in vivo and in vitro were all 
retained after mutation and coupling with dextran. The modified TCS 
protein has the same activities as nTCS, while the activities of DX-
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R29C and DX-173C conjugates were only slightly lower than nTCS. 
The ribosome inactivating activity and the abortifacient activity of the 
conjugates synthesized in the present study was only 20 times and 2.5 
times lower than nTCS respectively, while the conjugates made by 
dialdehyde method (Ko et al., 1991) get 200 times decrease in the 
former activity and 20 times reduction in the latter activity. This is 
because the coupling sites of DX-R29C and DX-K173C were far 
from the active site cleft of TCS, and therefore the dextran T40 
molecule wil l not sterically hindered the binding of substrate to TCS. 
As the dialdehyde method cannot couple dextran to a specific site on 
the TCS molecule, the lower activities may be explained by the 
masking of active site and steric hindrance imposed by the coupled 
dextran on TCS molecule. 
As the ribosome inactivation assay is a cell free system, the slight 
decrease in ribosome-inactivating activity of DX-R29C and DX-
K173C was probably due to the steric rigidity imposed on the TCS 
molecule by the dextran molecule which is very bulky and highly 
branched (Aspinall, 1983).This was supported by the observation that 
the digestion of dextran moiety by dextranase could restore the 
ribosome inactivating activity of TCS. Although digestion was not 
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complete ( see chapter 7) and there was still dextrin moiety remained, 
the most of the steric or bulky parts has been removed, therefore the 
activity was recovered. 
Other than the steric rigidity exerted on TCS by dextran molecule, an 
additional reason for the reduction in anti-tumour and abortifacient 
activities after coupling, may be the increase in molecular size of TCS 
rendered cellular entry of TCS more difficult. 
In the assay for the cytostatic effects on tumour cell lines, the 
conjugates DX-R29C and DX-K173C retained the activity of nTCS 
but with decreased potency. However, bromodextran also has similar 
inhibitory effect on tumour cell lines as nTCS, so it is difficult to tell 
whether it is the TCS or the bromodextran exert the action on the 
tumour cell lines, therefore it is difficult to quantify the effect of 
coupling on the cytostatic action of TCS on the two tumour cell lines. 
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Dose No. of No. of No. of % of % of aborted No. o< dead Mice 
Drugs (mg/25g) treated mice dead fetuses implantation site dead fetuses mice • 
nTCS 0.005 12 30 167 18% 8% o 
001 11 67 163 41% 45% 0 
0.02 7 76 94 81% 100% 0 
0-05 6 53 59 90% 100% 1 
0.1 7 111 111 100% 100% 0 
Table 6a; Midterm abortifacient activity of nTCS on pregnant mice 
Dose No.of No. of No. of % of % of aborted No. of dead Mice 
Drugs (mg/25g) treated mice dead fetuses implantation site dead fetuses mice • 
R29C 0.005 4 3 62 5% 0% q 
0.01 4 25 52 48% 50% 0 
0 0 2 9 128 139 92% 100% 0 
0.05 10 112 116 97% 100% 2 
0.1 9 92 94 98% 100% 3 
Table 6b: Midterm abortifacient activity of R29C on pregnant mice 
叙 Mice were considered aborted when the no. of dead fetuses exceeded 
50 % of the total implantation sites. . 
— … 
Dose No.of No. of No. of % of % of aborted No. of dead Mice 
Drugs (mg/25g) treated mice dead fetuses implantation site dead fetuses mice ‘ 
k173C — « — — — 
0.005 5 5 66 8% 0% 0 
0.01 6 46 85 54% 50% 0 
0 0 2 6 97 97 100% 100% 0 
, 0.05 6 75 75 100% 100% 1 
I 0 1 I 7 85 85 1 0 0 % 1 0 0 % 2 
Table 6c: Midterm abortifacient activity of K173C on pregnant mice 
Dose No. of No. of No. of % of % of aborted No. of dead Mice 
Drugs (mg/25g) treated mice dead fetuses implantation site dead fetuses mice • , 
DX- 0.005 10 17 71 24% 0% Q 
R29C 
0-01 10 25 75 33% 10% 0 
0.02 9 68 136 50% 55% 0 
0-05 8 92 97 95% 100% 0 
0.1 7 108 108 100% 100% 0 
0-2 5 69 69 100% 100% 0 
Table 6d: Midterm abortifacient activity of DX-R29C on pregnant mice 
* Mice were considered aborted when the no. of dead fetuses exceeded 
50 % of the total implantation sites. 
Dose No. of No. of No. of % of % of aborted No. of dead Mice 
Drugs (mg/25g) treated mice dead fetuses implantation site dead fetuses mice • 
DX- 0.005 8 29 95 31% 13% o 
K173C 
001 11 49 150 33% 27% 0 
0 0 2 8 57 122 47% 38% 0 
0-05 5 66 66 100% 100% 0 
0-1 6 82 86 95% 100% 0 
0-2 5 75 75 100% 100% Q 
Table 6e: Midterm abortifacient activity of DX-Kl 73C on pregnant mice 
Dose No. of No. of No. of % of % of aborted No. of dead Mice 
Drugs (mg/25g) treated mice dead fetuses implantation $rte dead fetuses mice * 
normal 0.3 ml/ 29 6 413 1% o% 0 
saline mice 
bromo 0.016g/ 7 4 100 4% 0% 0 
dextran mice 
Table 6f: control of midterm abortifacient activity assay 
(administration of normal saline and bromo dextran) 
农 Mice were considered aborted when the no. of dead fetuses exceeded 
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Chapter 7 Immunogenicity of Dextran-modified 
Trichosanthin conjugates 
7.1 Introduction 
Dextran was successfully coupled to modified TCS site specifically 
with well preserved biological activities, as described in the previous 
few chapters. However, as TCS is an immunogenic protein which 
elicit production of IgG and IgE antibodies (Ng et al., 1992, Xu et al 
1992). Anaphylaxis also appears after administration of TCS to 
HIV-infected pateints (Kahn et al., 1990, Byers et al., 1990). 
Therefore, the immimogenicity of the conjugates must be examined 
before it can be concluded that coupling to dextran has improved the 
therapeutic usage of the drug. We have to test whether the masking of 
the potential antigenic epitopes can reduce the immunogenicity of 
TCS. As IgG antibody is the major antibody of secondary immurie 
response, while IgE is important in eliciting immediate 
hypersensitivity or anaphylaxis, the potency of the conjugates to 





The method used in the immunization experiment was described in 
section 2.9.1. The immimogenicity of the conjugates was tested by 
immunizing C57 BL/6N inbred mice by injection of the antigens with 
or without adjuvant. The denatured forms of the proteins were also 
tested. The denatured proteins were administered without adjuvant. 
‘ I n the immimogenicity study of each conjugates , mice were divided 
into 3 groups and immunized with (i) 10 ug of nTCS (ii) 10 ug of 
R29C/ K173C/ R29C K173C (iii) DX-R29C/ DX-K173C/ DX-R29C 
K173C equivalent to lOug of nTCS. There were two control groups : 
mice injected with dextran equivalent to the amount present in the 
conjugates and mice with no immunization. The mice were primed on 
day 1 of the experiment, and the first and second boosters were given 
on day 21 and 35 respectively. 
The IgG and IgE levels were measured by an antibody capture 
approach with enzyme linked immunosorbent assay (ELISA). 
(Section 2.9.2.). The relative amount of IgG or IgE specific to nTCS 
was estimated by comparing the respective dilution (expressed as 
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mean±SEM) at aborbance of 0.5 which was found to be the most 
linear region of the IgG and IgE dilution curves. 
The immunization experiment was also performed with DX-TCS 
conjugates with dextran moiety digested by dextranase to see whether 
the dextran component of DX-TCS conjugates is responsible for the 
.change in immunogenicity. 
7.3 Results 
7.3.1. Immunization experiments without denaturation of antigens 
(a) with adjuvant 
For the first booster, the dilution curves of IgE response against nTCS 
of the 3 conjugates were separately shown in Fig. 7d, h, 1 while IgG 
responses against nTCS were shown in Fig. 7c, g, k. 
Only DX-K173C produced significantly lower responses in both IgG 
and IgE levels (p<0.05) (Fig.7g and 7h). The IgG response of 
K173C modified protein was also lower than nTCS. Both IgG and 
IgE responses of DX-R29C and R29C did not show a significant 
lower (p<0.05) response than nTCS (Fig.7c and 7d). The DX-R29C 
K173C conjugate and R29CK173C got a lower IgG level (p<0.05). 
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However, there were no significant difference (p<0.05) in the IgE 
levels. (Fig. 7k, 71). 
The IgG levels for the second booster of the three conjugates are 
shown in Fig. 7e, 7i and 7m, while the IgE levels can be seen in Fig. 
7f, 7j and 7n. Again, no difference (p<0.05) in both IgG and IgE 
levels can be seen for coupled and uncoupled R29C (Fig.7e and 7f). 
The DX-K173C conjugate only got a lower (p<0.05) IgG level but not 
IgE level than nTCS or K173C (Fig.7i and 7j). The DX-R29C K173C 
conjugate also only got a lower (p<0.05) IgG level than nTCS (Fig.7m 
and 7n). 
Al l mice showed negative IgG and IgE responses towards dextran. 
Control mice (with no immunization) also gave negative antibody 
responses towards nTCS .Hyperiiiimumzed mouse sera, which was 
obtained by repeated injection of TCS, acted as positive control of the 
assay. The dilution curve was showed in Fig. 7a, 7b. The intra-assay 
and inter-assay coefficient of variance estimated for different assays 
were summarized in Table 7a, 7b. The intra-assay coefficient of 
variance was determined by measuring the same serum sample twelve 
times in one assay. The inter-assay coefficient of variance was 
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determined by measuring the same serum sample in duplicate in one 
run and repeated on six different assays. 
Intra-assay coefficient of 
variance 
I7E 3.50% 
I^ G 7.40% 
Table 7 a 
inter-assay coefficient of 
variance 
IgE 8.70% 
igG 8.01 % 
Table 7b 
(b) Without adjuvant 
For the first booster, both DX-R29C and DX-K173C showed 
significant lower IgG and IgE (p<0.05) responses as compared with 
nTCS or the modified TCS. (Fig. 7o, p, s, t). However, except IgE 
response of DX-R29C conjugate, there was only a partial but non-
significant recovery in antibody response after digestion of the 
conjugate with dextranase. 
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The DX-R29C K173C conjugate also got a significantly lower 
(p<0.05) IgE and IgG responses than nTCS. (Fig. 7w, Ix). 
Nevertheless, the reduction in the response was not lower than DX-
R29C and DX-K173C. The modified TCS, R29C, K173C and 
R29CK173C have same IgG and IgE levels (p<0.05) as nTCS. 
The differences in antibodies levels between the conjugates and the 
uncoupled TCS were obviously smaller in the second booster (DX-
R29C: Fig.7q, 7r, DX-K173C: Fig.7u, 7v, DX-R29C K173C : Fig.7y, 
7z). Only the DX-R29C K173C has a lower (p<0.05) IgG and IgE 
responses than nTCS. 
7.3.2. Immunization experiment with denaturation of 
antigens(without adjuvant) 
The IgG and IgE responses of the conjugates (DX-R29C and DX-
K173C) were much lower than nTCS and the modified TCS, with 
DX-K173C having a greater decrease in immunogenicity. (DX-R29C: 
Fig. 7ac, ad, DX-K173C: Fig. 7ae, af). Nevertheless, the digestion of 
the dextran component cannot resume the immunogenicity of the 
conjugates. 
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With the exception of the IgE response of R29C, the immunogenicity 
of the modified TCS protein was not significantly different from that 
of nTCS. 
7.4. Discussion 
Conjugation with dextran has shown be effective in reducing the 
immunogenicity of many therapeutic and biological active proteins. 
Conjugate between haemoglobin and dextran T20 was found to be 
non-immimogenic in homologous species (Cunnington et a/.,1981). 
Coupling of dextran T40, T70 or T250 to aspapaginase was able to 
eliminate anaphylactic reaction in multiple doses to rabbits. (Wileman 
et al1986). 
Coupling of dextran has also been shown to be able to reduce the 
antigenicity of TCS (Ko et al, 1992). In the present study, when the 
immune system was stimulated using adjuvant which is a non-specific 
immunostimulator, only DX-K173C showed a significant reduction in 
immunogenicity as compared with nTCS. DX-K173C gave 3 times 
less IgG and IgE level than nTCS when the dilution factors at 
aborbance of 0.5 were conpared. (For IgG, DX-K173C: 6080士888, 
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nTCS: 21500土 5855，for IgE, DX-K173C: 1052士 194, nTCS: 
2772±501). DX-R29C got no significant difference in 
immunogenicity from nTCS.. However, when adjuvant was not used, 
both DX-K173C and DX-R29C conjugates got a significant decrease 
in immunogenicity. The IgG and IgE level both decreased about 3 
times as compared to nTCS (For IgG, DX-K173C: 4800±900 
compared with nTCS: 12100土 1250, DX-R29C: 6200土690 compared 
with nTCS:21700±l600. For IgE, DX-K173C: 790士200, nTCS: 
2000士 228, DX-R29C: 740士 110, nTCS: 2590土490). The above 
findings can be explained by assuming that the 173rd position is more 
immunogenic than the 29th position. When the immune system was 
stimulated by adjuvant, the antibody response was high and close to 
the saturation point of immune system. Near the saturation point, the 
immune system is not sensitive enough to detect small difference in 
immunogenicity as in the case of coupled and uncoupled R29C . The 
coupling to the 173rd position resulted in large decrease in 
antigenicity, therefore could still be detected. When adjuvant was not 
used the immune reponse was far from saturation and so difference 
can be detected for both conjugates. In the second booster, the 
differences between the conjugates and the uncoupled TCS were 
^ ^ 163 
smaller than the first booster. Differences that can be seen in the first 
booster cannot be found in the second booster. This is because in the 
first booster, some of the immune responses still have not got to 
saturation point, but they were near to saturation in the second 
booster. 
The results also suggested that coupling of DX at 29th and 173rd 
position sterically protected TCS from immune cell recognition. 
Nevertheless, the DX-R29C K173C conjugate did not show a greater 
reduction in immunogenicity than DX-R29C or DX-K173C. It is 
probable that the dextran T40 has coupled to either one of the two 
sites only and thus, the DX-R29C K173C conjugate was just the same 
as a singly coupled conjugate. This is supported by the observation 
that DX-R29C K173C came out at same position as DX-K173C and 
DX-R29C in Sephadex G200 column (Fig. 5d, i, j ) , indicating the 
similar molecular weights. This is further supported by the similar 
molecular weights in SDS-PAGE (Fig. 5k, kl). 
As compared to the result of Ko et al., 1992, the decrease in 
immunogenicity after coupling is smaller. This is due to the fact that 
the dialdehyde method used by Ko et al, (1992) was able to couple 
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more than one dextran (1.8 dextran per TCS on average) to TCS, and 
so most of the antigenic epitopes are covered by dextran. In the case 
of asparaginase and haemoglobin, there were also more than one 
dextran molecules attached to the protein concerned (Cunnington et 
al., 1981 and Wileman et al., 1986), the reduction in immimogenicity 
were very significant. In the present method, there was only one 
dextran coupled to TCS, there was still exposure of antigenic epitopes 
for immune recognition. 
After dextranase digestion, the immimogenicity of the conjugates was 
only partially and non-significantly recovered. This is probably the 
result of incomplete digestion of the dextran moiety. As seen from 
SDS-PAGE, the molecule weight did not returned to 26 kDal after 
digestion (Fig. 7aa, Tab). 
When the immunization experiments was carried out with prior 
denaturation of the antigens, there was a reduction in inununogenicity 
of the conjugates as compared to nTCS, with DX-K173C having a 
larger effect. After denaturation, the 3-dimenional epitopes of TCS 
was discrupted, antibodies or immune cells can only recognise linear 
sequence of amino acids. Therefore, it can be concluded that the 
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amino acid sequence near the 29th and 173rd position were both 
important for antibody recognition, with the 173rd position more 
immunogenic. The immunogenicity of the conjugate could not be 
recovered by dextranase digestion. This was also observed when 
immunization was done without denaturation of antigen. As 
mentioned above, this was due to incomplete digestion by dextranase, 
and therefore the amino acid sequences near the two positions were 
still masked by the remaining dextrin moiety. 
As in the case for haemoglobin and asparaginase (Cunnington et 
a/.,1981 and Wileman et al., 1986), the conjugates in the present 
study did not elicit the production of antibodies against dextran. In 
this aspect, the present conjugates are better than conjugate 
synthesized by dialdehyde method which give conjugates eliciting IgG 
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Figure 7a : Dilution curve of hyperimmune mosue sera. 
TCS specific IgG was detected on nTCS coated microtitre plate. 
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Figure 7b: Dilution curve of hyperimmune mouse sera. 
TCS specific IgE was detected on nTCS coated microtitre plate. 
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Figure 7c : Dilution curve of IgG of different mose sera 
on TCS coated microtitre plate, (with adjuvant first booster) 
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Figure 7d : Dilution curves of IgE of different mouse sera 
on TCS coated microtitre plate. 
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Figure 7e : Dilution curves of IgG of different mouse sera on TCS 
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Figure 7f: Dilution curves of IgE of different mouse sera on 
TCS coated plate (with adjuvant, second booster) 
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Figure 7g : Dilution curve of IgG of different mouse sera 
on TCS coated microtitre plate. 
(with adjuvant, first booster) 
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Figure 7 h: Dilution curves of IgE of different mouse sera 
on TCS coated plate, (with adjuvant first booster) 
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Figure 7i : Dilution curve of IgG of different mouse sera 
on TCS coated microtitre plate (with adjuvant, second booster). 
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Figure 7j : Dilution curves of IgE of different mouse sera 
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Figure 7k: Dilution curves of IgG of different mouse sera 
on TCS coated microtitre plate. 
(with adjuvant, first booster) 
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Figure 71 '.Dilution curves of IgE of different mouse sera 
on nTCS coated plate (with adjuvant, first booster) 
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Figure 7m-. Dilution curves of IgG of different mouse sera 
on TCS coated plate (with adjuvant, second booster) 
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Figure 7n5 Dilution curves of IgE of different mouse sera 
on nTCS coated plate (with adjuvant, second booster) 
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Figure 7o j Dilution curves of IgG of difference mouse sera 
on TCS coated microtitre plate. 
(without adjuvant, first booster) 
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Figure 7P:Dilution curves of IgE of different mouse sera 
on TCS coated microtitre plate, 
(without adjuvant, first booster) 
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Figure 7q: Dilution curves of IgG of different mouse sera 
on TCS coated plate (without adjuvant, 2nd booster) 
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Figure 7 r : Dilution curves of IgE of different mouse sera 
on TCS coated plate (without adjuvant, 2nd booster) 
^ ^ ^ ^ ^ ^ 184 
1.2 
• DX-K173C 
^ ^  (dextranase digested) 
1 . 0 - X 
全 • K173C 
T \ • DX-K173C 
0.8 卜 i • nTCS 
丄 \ \ \ 
§ 0.6 - \ \ f \ 
" \ i \ \ 
0 . 1 
0.2 . 
0 . 0 ‘ ‘—1““1~I I I I 1 I 零 ， ， ， 罾 : “ I 
103 104 105 
Dilution factor 
Figure 7s: Dilution curves of IgG of different mouse sera 
on TCS coated microtitre plate. 
(without adjuvant first booster) 
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Figure 7t： Dilution curves of IgE of different mouse sera 
on TCS coated microtitre plate, 
(without adjuvant, first booster) 
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Figure 7 u: Dilution curve of IgG of different mouse sera 
on TCS coated plate (without adjuvant, 2nd booster) 
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Figure 7 Dilution curves of IgE of different mouse sera 
on TCS coated plate ( without adjuvant, 2nd booster) 
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Figure 7w ： Dilution curves of IgG of different mouse sera 
on TCS coated microtitre plate. 
(without adjuvant, first booster) 
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Figure 7x： Dilution curves of different mouse sera 
on TCS coated microtitre plate. 
(without adjuvant, first booster) 
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Figure 7y: Dilution curves of IgG of different mouse sera 
on TCS coated plate (without adjuvant, 2nd booster) 
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Figure 7 z ： Dilution curves of IgE of different mouse sera 
on TCS coated plate (without adjuvant, 2nd booster) 
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Lane 1 : DX-K173C 
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Figure 7ab〗 SDS-PAGE analysis of DX-R29C and digestion by 
dextranase “ ‘ 
Lane 1 : DX-R29C 
Lane 2 : DX-R29C (dextranase digested) 
Lane 3 : nTCS 一 
Lane 4 : Low molecular weight marker 
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Figure 7 ad: Dilution curves of different mouse sera 
on TCS(denatured) coated plate. 
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Figure 7ae： Dilution curves of IgG of different mouse sera 
on TCS(denatured) coated plate. 
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Animal and human pharmacokinetic studies revealed that TCS had 
very short plasma half-life in the order of minutes to hours (Kahn et 
al., 1990 and Ko et aL, 1991). The drug is accumulated in the kidney, 
suggesting that it may be an important organ for TCS elimination (Lau 
et al., 1980 and Ko et aL, 1994). TCS is a low molecular weight 
protein and therefore it is filtered and reabsorbed by the kidney. Our 
previous study showed that TCS competed with hemoglobin for 
tubular reabsorption through a saturable process. Because of the 
ribosome inactivating nature, reabsorption of TCS may cause 
impairment of protein synthesis in tubular cells leading to renal 
dysfimction. It was indeed shown in a previous study that acute 
infusion of TCS resulted in reduction of glomerular filtration rate 
(GFR). Such decrease is not observed when TCS is coupled to a 
macromolecule dextran. The dextran-TCS is a large complex and is 
excluded from glomerular filtration. These studies suggest that TCS is 
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nephrotoxic when it is present in the lumen of the renal tubules (Ko et 
al., 1991 and Ko et al1994). 
The mechanism of TCS toxicity may be due to the direct inhibitory 
effect of protein synthesis (Maraganore et al., 1987, Wang et al., 
1987 and Yeung et al., 1988), which affects cells with continuous or 
high protein turnover. Another possible mechanism may be related to 
the basic pi of TCS, which renders TCS resistance to lysosomal 
digestion and subsequently tubule cells damage due to protein 
overloaded (Psece et al., 1980 and Maack, 1992). The present study 
attempts to coiifmn and identify the site of TCS induced 
nephrotoxicity by examining the structural and functional alterations. 
The effect of coupling on the nephrotoxicity of TCS was also studied. 
8.2 Method 
The procedure described in section 2.10 was used. In the functional 
study, after 2 days of equilibration in metabolic cages, single dose of 
nTCS was injected peritoneally into Sprague-Dawley rat (350 - 400 
g). The dosage used ranged from 0.03 mg to 4.8 mg (0.03, 0.3, 0.6, 
2.4 and 4.8 mg). On the 2nd and 3rd day after injection, 2 rats from 
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each dosage group were euthanized after removal of both kidneys for 
morphological study. Others were carried on in the metabolic cages 
for 10 days and then euthanized. The 24 hour creatinine clearance and 
urine sodium excretion was monitored. The urine protein 
concentration was determined by the Lowry method as described in 
section 2.1.2. Urine protein composition was analyzed by SDS-
polyacrylamide gel electrophoresis. The nephrotoxicity of DX-R29C 
and DX-K173C was also studied by administration of conjugate 
equivalent to 2.4 mg of nTCS. Control was done by injection of 
normal saline or Br-DX equivalent to amount present in the 
conjugates. Statistical analysis was done by one way analysis of 
variance with significant level of p<0.05. 
Kidney tissues were fixed and processed for light and electron 
microscopy as described in section 2.10.2. For electron microscopic 
o 
examination, the sections were studied independently by two people 
in a single blinded manner. A semiquantitive grading for the extent of 
cell necrosis in proximal tubules was used. 
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8.3 Results 
8.3.1 Functional study on nephrotoxicity of natural TCS 
The method was described in section 2.10. Two rats in the group of 
animals receiving 4.8 mg of nTCS died on the 3rd day after injection. 
Microscopy of their kidney tissues showed extensive autolysis. The 
data from these 2 rats were therefore excluded from this study. All 
other rats which were not euthanized for morphological study 
survived the 10 days period. Renal flmction was significantly lowered 
after TCS injection with dosage 0.3 mg and above (Fig.8.la ). As 
there were no significant difference (p<0.05) between groups 
receiving 0.3 and 0.6 mg , and also between 2.4 and 4.8 mg, the rats 
were divided ,into just two groups : a low dosage group (receiving 0.3 
and 0.6 mg TCS) and a high dosage group (receiving 2.4 and 4.8 mg 
nTCS). The significantly lower (p<0.05) creatinine clearance in the 
high dosage group than the low dosage group indicates a dose 
dependent effect. Creatinine clearance of rats receiving a much 
smaller dose of 0.03 mg was unchanged and same as control. On the 
2nd day after injection of 2.4 mg of TCS, urine protein excretion was 
slightly elevated but not statistically significant (Fig. 8.1e ). In view of 
the decreased renal flmction, the daily protein excretion is believed to 
be enhanced. Nature of the urinary protein is mainly having molecular 
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weigh below 70,000 daltons (Fig. 8 . I f ) . While plasma sodium and 
potassium concentration were stable(Fig.8.1b and 8.1c) ’ urine Na 
excretion (as indicated by value ofUNaV) was significantly depressed 
after TCS injection (Fig.8.Id). Administration of dextran and normal 
saline (control group) has no effect on UNaV. 
8.3.2 Morphological study on the nephrotoxicity of natural TCS 
A. Light Microscopy findings 
The glomeruli were unremarkable in all the animals studied (Fig.8.2a). 
There were also no significant abnormality identified in mesangial, 
endothelial and epithelial cells. Following TCS injections, recognized 
tubular changes included: (1) spotty tubular cell necrosis, (2) 
increased hyaline droplets in proximal tubules, (3) increased tubular 
hyaline casts, (4) attenuation of proximal tubular brush border, and (5) 
mitosis of tubular epithelial cell (Figure 8b-8h ). These abnormalities 
were focal, patchy, and were observed in one or two cells in the same 
tubule. Usually only scattered tubules showed the lesions, while most 
of the remaining tubules were well-preserved. There was no 
interstitial cellular infiltration or edema. Lymphocyte, 
polymorphonuclear neutrophils or eosinophils were not identified in 
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the interstitium or in the vasa recta of medulla. Also there was no 
abnormality identified in the blood vessels. 
B. Ultrastructural findings: 
Samples from 16 rats including 2 controls were prepared for 
ultrastructural study. Glomeruli in all rats examined appeared to be 
ultrastructurally well-preserved (Fig.8.2i). No electron dense immune 
deposit or cellular proliferation was found. The foot plate and 
processes of podocytes were intact. A few visceral epithelial cells 
exhibited mild activation with conspicuous but intact cytoplasmic 
organelles. 
For proximal convoluted tubules, all rats examined showed various 
degree of tubular necrosis with the exception of one rat which 
received the dose of 0.3 mg of TCS. Most of the necrotic cells were 
scattered among adjacent viable cells, in which autophagosomes were 
occasionally observed (Figure 8.2j). They exhibited condensed cytosol 
with discernible cytoplasmic membrane and brush border. The basal 
lamina was intact. Dead cell cast and disrupted organelles were seen 
in the lumen (Figure 8.2k). Tubular cell necrosis was observed in all 
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three segments of the proximal tubules. The extent of necrosis was 
more severe among those rats received high dose of TCS (Table 8a). 
An increase in number and size of lysosomes were observed in all but 
2 rats examined (Figure 8.21). This observation was consistent with 
the hyaline droplets found under light microscopy. Large residual 
bodies were present in those cases with frequent necrosis and often 
adjacent to necrotic cells (8.2m). 
With respect to the cellular organelles, there was no pathology in the 
ribosome and rough endoplasmic reticulum. Nevertheless, swollen 
mitochondria and condensed cytoplasm were observed (Fig.8.2n). The 
apical phagocytic apparatus was preserved in the viable tubular cells. 
However, focal loss of basolateral interdigitation was noted (Figure 
8.3k). The nuclear chromatin in the necrotic cells was condensed, but 
no feature of typical apoptosis was recognized. Although margination 
of neutrophil was suggested in some cases, no extravasation of 
inflammatory cells was found. Normal proximal tubule from control 
rat is shown in Fig.8.2o. There was moderate number of lysosomes , 
and no feature of cell damage was seen. 
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The Loop of Henle in the medulla showed neither tubular degeneration 
nor necrosis. Occasional luminal cell debris were seen while the 
tubular epithelium is intact (Fig. 8.3p). Loop of Henle of control rat is 
shown in Fig.8.2q. 
While luminal debris and casts were observed in distal nephrons of 
almost every rats, cellular necrosis were only seen in 4 out of 14 cases 
examined (Fig. 8.3r). Fig. 8.2s shows the morphology of normal distal 
convoluted tubules. 
There was no abnormality found in the collecting ducts. (Fig. 8.2 t) 
8.3.3 The effect of coupling of Dextran T40 on the nephrotoxicity 
of TCS. 
The effect of administration of DX-R29C and DX-K173C on 
creatinine clearance and UNaV ,compared with injection of 
equivalent amount of nTCS (2.4 mg) is shown in Fig.8.3a-8.3d. 
Although injection of the two conjugates resulted in significant 
decrease (p < 0.05) in creatinine clearance and UNaV, the reduction 
was smaller than that of nTCS. 
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8.4 Discussion 
Although histological abnormalities were only identified in isolated or 
focal group of tubular cells, which can be argued on the specificity of 
these findings, the association of these structural lesions with renal 
dysfunction such as proteinuria and reduced creatinine clearance in all 
animals treated with TCS supports a cause and effect relationship. In 
the absence of glomerular and vascular lesions, morphological 
changes in renal tubules substantiate the previous suggestion of 
tubular toxicity caused by TCS (Ko et al., 1991, Ko et al., 1994). The 
different degree of renal dysfunction (Fig.8.la) and morphological 
lesion (Table 8a) at low dose (0.3-0.6 mg TCS) and high dose of TCS 
(2.4-4.8 mg TCS) suggests that the toxicity is the consequence of 
direct drug effect. Hypotension and anaphylactic reaction in rats 
treated with TCS are not obvious from this and previous studies 
(8,10), making renal ischemia and immunoreaction an unlikely 
contribution to the observed renal dysfimction. 
The sodium excretion (as indicated by UNaV) was significantly 
depressed (p<0.05) upon TCS administration , this could be the result 
of decreased GFR , increased reaborption or reduced food / sodium 
intake. However, the GFR is the major factor affecting UNaV, 
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therefore UNaV is still a good indicator of renal function, and it 
provides a second evidence, other than creatinine clearance, for the 
effect of TCS on renal fiinction. 
Proteinuria was not obvious by measuring the daily protein excretion 
(Fig.S.le). There was only a slight but not statistical significant rise in 
daily protein excretion after TCS injection. However the creatinine 
clearance of these rats were reduced by more than 50% and if daily 
protein excretion is unchanged, it means that fractional protein 
excretion must be increased. Under physiological condition, most of 
the plasma protein cannot pass through the glomerulus due to their 
high molecular masses, but some small molecular weight proteins are 
filtered through glomerulus and reabsorbed by the proximal tubule 
(Maack,1992). In this study, nature of the urinary protein is mostly 
having molecular weight under 70,000 daltons and increased 
fractional excretion of these protein supports proximal tubular lesion 
which is consistent with the present morphological findings of intact 
glomerulus but injuries in proximal tubules. The damages were 
restricted to the proximal tubule which is the most active portion of 
nephron to absorb and metabolize filtered proteins. 
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The decreased glomerular filtration rate after TCS observed in both 
the present and previous studies may be explained by the proximal 
tubular injury. Such alteration of glomerular filtration rate may be 
related to tubular obstruction and backleak mechanisms. Focal tubular 
dilatation, necrosis and granular casts all participate to these 
mechanism of renal failure (Dunnill and JeiTome,1976, Olsen and 
Olsen, 1984 and Brezis et al., 1993).Neverthless, the above 
mechanisms cannot account for the large (over 50%) decrease in 
GFR, as the degree of damage of tubular cells and the presence of 
tubular cast were low (lower than 20%) as seen in light or electron 
microscopy. The large reduction in GFR can only be explained by 
tubuloglomerular feedback mechanism which lower GFR whenever 
the solute delivery or solute concentration at the mucula densa is 
raised. The tubuloglomerular feedback are modulated by the renin-
angiotensin system , and recent evidence has shown that increase in 
distal urine sodium may lower renin synthesis by macula densa 
(Brezis et a l , 1993). TCS might have affected the sodium 
reaborption in the proximal tubule and caused increase in sodium 
cocentration , and therefore modulation of tubuloglomerular feedback 
to reduce the GFR. 
However, the causes and pathogenesis of tubular toxicity of TCS are 
largely unexplained. Two possible mechanisms may be operative. 
Firstly, this may be related to the direct action of TCS in impaired 
protein synthesis, a vital process to those cells with a rapid protein 
turnover. In this process, the proximal tubule is the main segment 
exposed to the filtered TCS, coupled with the augmented effect due to 
active uptake of the drug. As a result, the proximal tubule showed 
more conspicuous necrosis, while the distal delivery of the drug is 
minimized leading to less toxicity in the distal segments. The net 
result will be an accumulation of TCS in the vulnerable proximal 
tubules while the distal part of the nephron may be relatively spared. 
Secondly, TCS may be resistant to lyzosomal hydrolysis with 
subsequent intracellular accumulation of the drug or its metabolites 
and leakage of lysosomal contents, exerting its detrimental effects. 
Such a mechanism has been described in nephrotoxicity of low 
molecular weight proteins such as immunoglobulin light chains, 
myoglobin and lyzozyme (Sanders et al., 1988 and Cojocel et al, 
1982). Electron microscopic study of acute inunimoglobin perfusion 
of the proximal tubule showed increased lysosomal density and size 
which were associated with deteriorated GFR and impaired tubular 
functions (Sanders et al., 1988). Leakage of lysosomal content and 
formation of distal tubule cast were proposed as the intermediate 
events. In the present study, the increased number and size of 
lyzosomes, the presence of giant forms, myeloid body-like figures and 
autophagosomes suggest that TCS induced nephrotoxicity may 
operate in a similar mechanism. 
The focal distribution of necrosis, the subtle ultrastructural injury and 
the visible mitosis in tubular epithelium suggest that the nephrotoxicity 
in the studied doses is likely reversible. This is supported by the 
observation on improved GFR in rats 10 days following the single 
injection of same dose of TCS. In this study, the dosage of 4.8 mg 
which killed 2 of 5 animals approached that of the median lethal dose 
(LD50)，however the mechanism leading to the death of these rats was 
not identified. This is the first morphological and functional 
description of the nephrotoxicity of TCS. A different form of 
extensive confluent tubular necrosis was also observed after treatment 
with other ribosome inactivating proteins (Stirpe et cd., 1987 and 
Batelli et al., 1990). 
In early studies of renal toxicity and acute renal failure, extensive 
tubular necrosis was observed with strong toxic substances, often 
L 211 
confounded by autolysis as the experimental animals died (Dunnill 
and Jerrome,1976, Olsen and Olsen, 1984 ). It is believed that the 
experimental animals in this study demonstrated the pattern of toxic 
tubular injury which is in contrast with the patchy distribution of 
ischemic lesion. Nevertheless, differentiation between the two 
mechanisms are sometimes difficult (Brezis et a l , 1993). It may 
require acute study using high lethal dose to amplify the process and 
extensive sampling for morphological assessment. 
Coupling of TCS to dextran reduced the nephrotoxicity of TCS, as the 
increase in molecular weight reduced the glomerular filtration of TCS. 
The elimination of nephrotoxicity after coupling to dextran T40 is also 
seen in acute infiision of TCS (Ko et al., 1994). However, there was 
still a significant reduction of GFR and UNaV in the present study. It 
is because there should be only one dextran molecule coupled to 
mutated TCS , thus the molecular weight of the conjugate was around 
66 kDal. With this molecular weight, some of the conjugates was still 
able to pass through the glomerulus and caused damage to tubular 
cells. 
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In conclusion, the present study confirms that TCS is nephrotoxic and 
the site of lesion is mainly in the proximal convoluted tubule. 
Coupling of TCS to dextran T40 was able to reduce the 
nephrotoxicity of TCS. 
Table 8a. The number of rats showing difference degree of proximal convoluted tubular 
‘necrosis after injection of high and low doses of TCS. 
Numbers of rats with various degree 
ofPCT necrosis 
nil I + 丨 + + 
Low Dose 1 3 3 
(0.3-0.6 mg TCS) 
High Dose 0 1 6 
(2.4-4.8 mg TCS) 
nil No evidence of necrotic tubular cell 
十 Occasional necrotic cells present in the PCT, less than 
one in 5 tubules 
++ Frequent necrotic cells seen, at least one necrotic cell 
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Figure 8.1a : The perentage change in 24 hours creatinine 
clearance before and after TCS injection. 
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Figure 8.1b: The effect of TCS on serum sodium concentration 
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Figure 8.1 e ： Daily urinary protein excretion before and after 
2.4 mg TCS injection. 
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Figure 8.2a :Light microscopy shows normal glomerulus (PAS lOOx) 
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Figure 8.2b ： Light microscopy showing necrotic cells (arrow) in the 
proximal tubule ( H and E, 150x) 
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Figure 8.2c ： Mitosis (arrow) in the tubule is found occassionally in 
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Figure 8.2d : Patchy cortical region with extensive hyaline droplets 
changes of proximal tubules (PAS, 50x) 
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Figure 8.2e :This focus of the proximal tubule shows several necrotic 
(arrows) proximal tubule epithelial cells among tubular 
cells with swollen cytoplasm (H and E，15Ox) 
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Figure 8.2f: Individual necrotic tubular cells (arrow) with 
cytoplasmic eosinophilia and pyknotic nuclei scatter in 




Fi卯re 8 22 . High power veiw from the same section in 8.2f. A 
Figure S.2g-H^^P。。丨丨 ^^  present in the centre.、^^ent 加々 = ) 
cell shows swollen cytoplasm (arrow) (H and E，iDUx) 
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Figure 8 2h : Hyaline droplets in the proximal tubules. The glomeruli 
are unremarkable (PAS, lOOx, after 4.8 mg TCS) 
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Figure 8.2i: The glomerulus shows normal morphology in all 
components，including mesangial cells, endothelial cells 
and podocytes. The basement membrane is also free of 
deposit (SOOOx). 
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Figure 8.2 j : Necrotic cell in the proximal tubule. Tubular cell cast 
and phagocytosis of altered organelles by the adjacent 
viable epithelial cells are seen. The basal lamina is 
intact (3150x, after 2.4 mg TCS). 
r -
Figure 8.2k: The proximal tubule cell shows attenuation of microvilli 
(arrow) and basolateral interdigitation. Larae residual 
body (RB) is present in the cytosoL probablv oriainated 
trom an autophagosome. Organelle debris are also seen 
inside the lumen (L) (3150x after 2.4 mg TCS) 
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Figure 8.21: The cytosol is filled by lysosomes of different sizes in 
this proximal tubular cell. The apical phagocytic 






Figure 8.2m : Irregular cytoplasm residual body (RB) and laminated 
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Figure 8.2n ： Two necrotic tubular cells show markedly condensed 
chromatin，swollen mitochondria and cytoplasmic 
condensation (5000x). 
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Figure 8.20 ： The proximal tubule from a control rat shows a moderate 
number of lysosomes in the cytoplasm. No feature of cell 
damage is evident (3150x). 
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Figure 8.2p : The segment of thick limb of loop contains a cell cast 
. of proximal tubule in origin with discernible microvilli 
The loop epithelium is unremarkable. Althouah this 
segment is prone to ischemic insult no feature of 
sublethal injury or necrosis is observed (3150x after 




Figure 8.2q ： An electron micrograph taken from the medulla of a 
control rat, several limbs of the loop ofHenle are 




Figure 8.2r : A necrotic cell (arrow) in the distal convoluted tubule 




Figure 8.2s ： Unremarkable morphology from the distal convoluted 
tubule of a control rat (5000x). 
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Figure 8.2 t ： Electron micrograph from a control rat shows the 
structure of collecting duct with an intercalated cell 
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Chapter 9 General Discussions 
Coupling of biological active or therapeutic protein to a carrier such 
as homologous albumin (Poznansky et al., 1982), polyethylene glycol 
(Bendich et al., 1982, Hershfield, et al., 1991) or dextran (Wileman et 
al., 1986，Cunnington et al, 1981) have proved to increase the 
therapeutic use of the proteins. Among the carriers, dextran is more 
preferable than the other two due to its low toxicity and low 
inununogenicity. 
The enzyme asparaginase (used regularly in treatment of acute 
lymphoblastic leukemias) has been coupled to dextran TIO, T40, T70, 
T250 by dialdehyde method (Wileman et al., 1986). Although 
coupling decreases the enzyme activity, the conjugates were resisant 
to proteolysis by proteases and inactivation by asparaginase antibody. 
There was no type I I I hypersensitivity or anaphylaxix when the 
conjugates were administrated in multiple doses to rabbits. Coupling 
to dextran of size 40 kDal or larger effectively prevents antibody 
mediated clearance of the protein. Dextran-asparaginase conjugate 
has enhanced plasma persistence (Shewood et al., 1977). 
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Dextran-haemoglobin has once considered as potential blood 
substitute (Tarn et al., 1976). After conjugation (by using alkylation 
or dialdehyde method), the conjugates retained the oxygen binding 
affinity of native haemoglobin with increased plasma persistence, but 
found to be non-immunogenic in homologous species (Cunnington, 
1981). 
Polyclonal and monoclonal antibodies reactive against tumor-
associated antigen have potentiality in the treatment of tumors. 
Murine and rabbit iinmunoglobins have been coupled to small 
molecular weight dextran (MW 6000 土 500) by dialdehyde method 
(Fagnani et a/., 1990). The immiinoreactivity was found to decrease 
with increasing number of dextran molecules attach to the antibody. 
Multiple infusions of the conjugates do not elicit measurable immune 
,response, while the tumor localization properties of the antibodes 
were retained. 
Trichosanthin is a purified plant protein that possesses various 
biological and pharmacological activities. Its abortifacient activity has 
long been known (Jin., 1985, Liu et al., 1985, Liu et al., 1991). It is 




1985, Huang, 1987). Recent finding of its anti-HIV activity (McGrath 
et a l , 1989) aroused considerable research interests. However, its 
clinical application is limited by its short plasma half life and 
immunogenicity (Ng et a/., 1992, Xu et al., 1992). In order to 
overcome these shortcomings, Ko et al (1991) coupled dextran T40 
to TCS by dialdehyde method, which couples dextran to amino group 
of a protein. This method successfully reduces renal and non-renal 
clearance rate due to expanded molecular size. DX-TCS conjugate 
was shown to elicit less TCS specific IgG and IgE in mice (Ko et al., 
1992). However, the biological activities of the conjugate were 
dramatically reduced (Ko et al., 1993). This is probably the result of 
masking of the active site of TCS by dextran. 
In the present study, in order to reduce the loss in biological activities 
while still retain the low immunogenicity of the conjugate, dextran 
was coupled to TCS at potential antigenic sites which are distant from 
the active site (Glu 160). This was achieved by creating a cysteine 
residue at suspected antigenic site using site-directed mutagenesis 
technique. Making use of the absence of sulphydryl group/cysteine 
residue of natural TCS, alkylation method was utilized to couple 
dextran site specifically to the sulphydyl group of the modified TCS. 
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An efficient system for the expression and purification of three 
modified TCS (R29C, K173C and R29C K173C) has been 
developed. The purified TCS were ready for coupling with 
bromoacetyldextran. 
The immunogenicity of DX-R29C and DX-K173C were found to be 
significantly reduced. This suggests the dextran molecule sterically 
. protect TCS from immune recognition. Both IgE and IgG responses 
were 3 to 4 times lower compared with nTCS when no adjuvant was 
used for immunization. Reduction in IgE level means a lowered 
chance of anaphylactic or hypersensitivity reaction. IgG is the major 
immunoglobulin to be synthesized during secondary response, so the 
decrease in IgG response makes the multiple infusions of TCS much 
safer. Besides, immunization without adjuvant resemble the natural 
condition for the administration of the drug to patients. All these new 
findings about immunological activities of the Dextran-trichosanthin 
conjugates help to improve the therapeutic application of the drug. 
The 173rd position of TCS appeared to be more immunogenic. This 
is consistent with the results of Ke et a/.(1988) who found that one of 
the epitope of TCS is located between sequence positions 107 and 
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234. The immunogenicity of the conjugates was significantly reduced, 
but the biological activities were well preserved with minimal loss in 
potency. This is due to the masking of antigenic epitopes but not the 
active site of TCS. 
The decrease in ribosome-inactivating activities after coupling was 
smaller compared with coupling by dialdehyde method (Ko et al., 
1994). The greater reduction in this activity using dialdehyde method 
must be the result of masking of active site of TCS by dextran 
molecule. This is supported by the evidence that the binding of 
monoclonal antibody close to the active site of a-MMC (another type 
I RIP which is highly homologous to TCS) diminishes the activity 
drastically, while the activity is well preserved when the antibody 
binds far away from the active site (K.C. Leung, Ph.D. thesis, 
1994).The in vivo abortifacient activity was also well retained. The 
increase in molecular size of TCS has a small influence on the cellular 
entry of TCS into the syncytiotrophoblasts which is phagocytic in 
nature. 
TCS was found to be nephrotoxic and it affects mainly the proximal 
convoluted tubule. The association of structural damage of tubular 
248 
cell with renal dysfunction suggests a cause and effect relationship. 
The dose dependent effect of the drug means the toxicity is due to 
direct action of TCS. Mild small molecular weight (under 70 kDal) 
proteinuria is consistent with the morphological findings of proximal 
tubular lesion. The decrease in GFR and renal dysfunction may be 
explained by tubular obstruction and backleak mechanisms ( Dimnill 
and Jerrome, 1976 , Olsen and Olsen, 1984 , Brezis et a l , 1993). 
Coupling of Dextran successfully decreases the nephrotoxicity of TCS 
probably by preventing TCS from getting into the tubular space to 
exert its toxicity. The effect of reduced toxicity is more obvious in the 
first few days after administration of the drug, during which the renal 
toxicity of TCS is most prominent. 
» . . • 
。With significant decrease in immunogenicity and nephrotoxicity, but 
well preserved biological activities both in vitro and in vivo, coupling 
of DX T40 to modified TCS has made TCS a better potential 
therapeutic agent. However, there is still further work that can be 
done. 
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In the present study, the reduction in IgE level after coupling is 3 to 4 
times, which is smaller than that of dialdehyde method (Ko et al., 
1992) which got 8 times decrease in IgE level. This is probably due 
to the larger number of dextran molecules that was coupled to TCS 
(Seppala and Makela, 1989). However, the reduction in 
immunogenicity of the R29C K173C after coupling was not higher 
than R29C or K173C. As mentioned earlier, only one dextran 
molecule may have been coupled to R29C K173C, so the conjugate 
behaved just like the singly coupled modified TCS. To get both sites 
coupled, the reaction conditions (especially increasing the molar 
ration of TCS to DX) may be changed. Other coupling sites (e.g. 
141st, 219th positions) that also get high antigenic indexes may be 
tried. I f two more dextran molecule can be coupled to TCS, the 
nephrotoxicity is likely to diminish further as the molecular size 
increases. 
Although the proximal tubule was found to be the predominant site of 
injury due to TCS nephrotoxicity, further investigation on the causes 
and pathogenesis of tubular toxicity of TCS is needed. The injury 
may be the result of the direct ribosome-inactivating action of TCS, 
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or leakage of lysosomal content due to intracellular accumulation of 
the drug. 
Work has to be done to confirm toxic tubular injury rather than 
ischemic lesion. This require acute study using high lethal dose to 
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